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ABSTRACT OF THE DISSERTATION 
 
Circadian and cardiovascular dysfunction in the Huntington’s disease mouse models 
by 
 
Saemi Park 
Doctor of Philosophy in Molecular, Cellular and Integrative Physiology 
University of California, Los Angeles, 2020  
Professor Christopher S. Colwell, Chair 
 
Circadian and sleep disruptions have been shown to lead to an increased risk for 
cardiovascular (CV) events. Huntington’s disease (HD) patients are reported to have various 
symptoms including circadian and motor deficits. In addition, CV symptoms are implicated as 
the cause of death in over 30% of the HD patient population. However, very little is understood 
about the intersection between circadian disruption, CV disease, and HD. Here we utilized two 
mouse models, BACHD and Q175, to investigate CV pathology in HD. Reduced diurnal and 
circadian resting heart rate rhythms, heart rate variability, and baroreceptor reflex support that 
the autonomic regulation of the CV system is compromised in both HD mouse lines. In addition, 
age-dependent reduction in the heart function and cardiac fibrosis were observed. These results 
led us to test the hypothesis that reducing the mutant huntingtin (mHtt) expression in the 
cardiomyocytes is sufficient to rescue CV symptoms seen in BACHD mice by crossing with the 
cardiomyocyte-specific Cre, Myh6-Cre. Our results show that reduced mHtt expression in the 
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cardiomyocytes help improve left ventricular ejection fraction, several heart disease markers, and 
grip strength, a behavioral marker of cardiovascular health in the BACHD mice.  Together this 
data indicates that heart disease in HD patients is likely to be driven both by cardiomyocyte 
specific pathology as well as dysfunction in the ANS.     
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Chapter 1: Do disruptions in the circadian timing system contribute to autonomic neuropathy in 
Huntington’s disease? 
Abstract:  
 
Huntington’s disease (HD) patients suffer from a progressive neurodegenerative process that 
inflicts both motor and non-motor dysfunction. HD is caused by a CAG repeat expansion within 
the first exon of the huntingtin (Htt) gene that produces a polyglutamine repeat that leads to 
protein misfolding, soluble aggregates, and inclusion bodies detected throughout the body 
including the heart. Both the clinical and preclinical research indicate that cardiovascular 
dysfunction should be considered a core symptom of at least a subset of HD patients. There is 
some evidence for cardiomyopathy, but these is even stronger evidence for dysautonomia 
(dysfunctional autonomic nervous system, ANS) in HD patients that can be detected early in the 
disease progression. The temporal patterning of ANS function is controlled by the circadian 
timing system based in the anterior hypothalamus. At the molecular level, circadian rhythms are 
generated by a transcriptional/translational feedback system that regulates transcription and has a 
major impact on cellular functions. Patients with neurodegenerative diseases including HD 
exhibit disrupted sleep/wake cycle and, in preclinical models, there is compelling evidence that 
the circadian timing system is compromised early in the disease process. We have been using 
preclinical models of HD to test the hypothesis that dysfunction in the circadian system 
contributes to the CV disease in neurodegenerative diseases. If correct, this work would lead to 
new therapeutic strategies and standards of care for HD and other neurodegenerative diseases. 
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Introduction: 
 
HD is a genetic determined neurodegenerative disease.   
Huntington’s disease (HD) patients suffer from a progressive neurodegenerative process that 
inflicts cognitive, psychiatric and motor dysfunction [1,2]. HD is caused by a CAG repeat 
expansion within the first exon of the huntingtin (Htt) gene which produces a polyglutamine 
repeat that leads to protein misfolding, soluble aggregates, and inclusion bodies detected 
throughout the body [3,4]. The normal function of the protein (HTT) is unknown; however, the 
mutated form leads to dysfunction of a broad range of cellular processes including cytoskeletal 
organization, protein folding, metabolism, and transcriptional activities. Based on the broad 
distribution of the HTT, the mutation would be expected to produce symptoms throughout the 
body. Indeed, recent work suggests HD alters function in the heart, testes, liver, muscle, as well 
as in the brain. HD is a genetic disease, and a large number of animal models have been 
developed, each with strengthens and weaknesses (see [5]). The work covered in this review was 
mostly conducted on the Q175, BACHD, R6/2, and R6/1 mouse lines.   
 
Cardiovascular dysfunction may be common in HD.   
Cardiovascular events are a major cause of early death in the HD population and occur at a 
higher rate compared to the rest of the population [6,7]. Possible cardiomyopathies have not been 
well explored in HD patients.  One recent study examined the electrocardiograms of over 500 
early symptomatic HD patients and found evidence for low heart rate (bradycardia) and 
conduction abnormalities in a significant fraction of the patients [8]. Preclinical models of HD 
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have found clear evidence for reduced contractility and cardiac output [9–14]. For example, a 
recent study of the cardiomyocytes of BACHD mice found evidence for increased 
calcium/calmodulin-dependent protein kinase II activity as well as structural abnormalities in the 
mitochondria [15]. The cardiac-specific expression of polyQ repeats leads to cardiovascular 
dysfunction, suggesting that cardiovascular disease may be the result of local abnormalities 
[16,17]. There is even stronger evidence for dysautonomia (dysfunctional autonomic nervous 
system, ANS) in HD patients that can be detected early in the disease progression.  The 
sympathetic nervous system appears to be most impacted during the very early stages of HD 
[18–20]. As the disease advances, the parasympathetic activity progressively decreases as well 
[20–22]. Therefore, both the clinical and preclinical research indicate that cardiovascular 
dysfunction should be considered a core symptom of at least a subset of HD patients. 
 
Sleep and circadian dysfunction are an integral component of HD pathophysiology.  
Sleep disorders are prevalent in HD patients and have detrimental effects on the daily 
functioning and quality of life of patients and their caregivers [23,24]. The most common 
symptoms found in these studies include a delay in sleep onset, fragmented sleep during the 
night, and daytime sleepiness.  Importantly, these disruptions in the sleep/wake cycle occur early 
in the disease progression and so could serve as a biomarker for HD as well as a target for 
interventions. The sleep/wake cycle is conceptualized as being driven by two, anatomically-
distinct processes: a homeostatic sleep mechanism (process S) as well as by the circadian timing 
system (process C). To date, there is little evidence that HD impacts sleep homeostasis but there 
is growing evidence for HD-driven disruption in circadian timing. Still, it is difficult to 
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determine whether the disease alters the circadian timing system in humans and animal models 
provide critical insights. Mouse models of HD also exhibit a progressive and rapid breakdown of 
the circadian rest/activity cycle that closely mimics the condition observed in human patients, 
typified by loss of consolidated sleep, increased activity during the rest phase, and more sleep 
during the active phase [10,25–27]. Importantly, the disruptions are seen under both light/dark 
(LD) cycle as well as the mice are held in constant darkness (DD). This latter step is critical to 
establish that the circadian system is compromised.  Disorganized circadian timing leads to 
undesirable effects throughout the body [28], altering the function of key organ systems 
including heart, pancreas, liver, lungs as well as the brain. Collectively this prior research 
supports the hypothesis that circadian dysfunction is an integral component of HD 
pathophysiology. We have been testing the hypothesis that dysfunction in the circadian system 
contributes to the CV disease in HD (Fig 1.1) and, in this review, we will summarize our 
progress. 
 
Topics: 
 
Baroreceptor reflex is blunted in HD 
One of the classic physiological tests of the ANS function is the measurement of the 
baroreceptor reflex in which changes in blood pressure (BP) evoke alterations in the heart rate 
(HR). Baroreceptors are mechanoreceptors located in the carotid sinus and aortic arch which 
sense the pressure changes. Although they are sensitive to both increases and decreases in 
arterial pressure, their primary role is to respond to a sudden fall in arterial pressure. This sudden 
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decrease is detected by baroreceptors and signals are sent to the medulla to elevate the 
sympathetic activity and reduce the parasympathetic activity. These changes lead to 
vasoconstriction and increased HR to bring back arterial pressure into the normal range. 
Recordings from the BACHD [29] as well as the Q175 [14] lines of HD mice indicate that the 
baroreceptor reflex is dramatically altered (Fig 1.2). The administration of Angiotensin II (ATII) 
or Nitroprusside (NP) leads to episodes of hypertension or hypotension, respectively. Changes in 
BP as a result of drug administration should elicit a compensatory response of HR via the 
baroreceptor reflex in order to normalize BP levels.  The Q175 mutants showed a dramatically 
blunted response in HR to the transient hypotension induced by NP suggesting that the 
sympathetic branch has impaired. The BACHD mutants showed a blunted response to both ATII 
and NP indicating both sympathetic and parasympathetic arms were impacted.  In both cases, we 
confirmed that there were no genotypic differences in the change in BP evoked by the injected 
drug as well as performed pharmacological controls to showing that appropriate receptor 
blockers prevented the change in HR.    
 
HD patients complain of dizziness and light-headedness upon standing, all symptoms of 
baroreceptor dysregulation resulting in orthostatic hypotension [18,30]. While not well 
documented in HD patients, orthostatic hypotension has been extensively examined in 
Parkinson’s Disease (PD) [31]. In this neurodegenerative disease, the neurogenic hypotension 
impacts about 30% of the patients with dizziness or lightheadedness, fatigue when standing, and 
difficulty walking to be the most common symptoms [32,33]. In a significant number of patients, 
the hypotension is responsible for the falls which one of the main complications of PD that has a 
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major impact on the quality of life. Patients with neurogenic orthostatic hypotension exhibit in 
enhanced reduction in systolic BP (~40 vs. 20 mmHg) in response to a stressor and thus are 
vulnerable for falls due to failure to maintain BP [34]. Like the PD patients, we expect that a 
subset of HD patients will be vulnerable to neurogenic orthostatic hypotension. 
 
Heart rate variability is reduced in HD 
HRV is a measure of variation in the beat-to-beat (R-R) interval that reflects the dynamic 
balance of sympathetic and parasympathetic control of heart function. Traditionally, HRV is 
generally considered an indication of cardiovascular health and low HRV proposed as a predictor 
for cardiovascular disease and mortality [35,36]. More recently, HRV has become a popular 
index of cardiac autonomic control in the biobehavioral sciences due to its relationship with 
stress disorders and other illnesses [37]. In humans, it is typically measured for short intervals 
and is increasingly available in health records as a non-invasive measure of cardiovascular 
function. One of the most commonly used methods for HRV evaluation is power spectral density 
analysis in which high-frequency (HF) and low-frequency (LF) bands are extracted from the 
HRV signal, and the spectral power is calculated (e.g., [38]). Traditionally, the LF power is 
viewed as a measure of regulation by the sympathetic branch of the ANS, although it is more 
likely a general index of ANS function [39,40].  
 
In our work, we measured HRV in WT and HD mutant mice over several days in both LD and 
DD conditions. In WT mice, HRV displayed a robust diurnal and circadian rhythm consistent 
with circadian regulation of the ANS (Fig 1.3). Both the LF and HF domains of the HRV 
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exhibited robust daily rhythms. In the Q175 line [14], the HRV was low in young mutants, and 
this reduction was largest during the rest phase. The power in the LF domain was significantly 
reduced in the young mutants with the most prominent effects during the night. A similar 
reduction in HRV was previously observed in the BACHD line [10,13] as well as in the R6/1 
model [41].  
 
In HD patients, a similar decrease in HRV has also been reported during the presymptomatic and 
early stages of HD progression [18,19,21]. Prior studies reported HRV deficits during the 
Valsalva maneuver, hand-grip test, and the head up tilt test in HD patients [20,22,42,43]. As far 
as we know, the spectral power analysis has not been carried out on data from patients. In human 
subjects, HRV changes with daily cycle and with sleep state (e.g., [44]) but we do not have this 
data from the HD patients. Thus, both the preclinical and clinical work is consistent with a 
disruption in the sympathetic branch early in the disease progression that is reflected as a 
decrease in HRV.   
 
Abnormal diurnal and circadian rhythms in HR observed in HD 
In humans and other animals, HR varies dramatically with acute physical demands, i.e. higher 
HR when we are physically active while low HR when sedentary. In addition to these acute 
changes, there are also robust 24-hr circadian rhythms in the heart and vasculature to prepare the 
cardiovascular system for higher output during the day in humans. Interestingly, these natural 
rhythms may increase the risk for vulnerable individuals and daily rhythms in the symptoms of 
cardiovascular disease peak in the morning hours (e.g., [45]).    
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In nocturnal mice, diurnal and circadian of cardiovascular output peak in the night. While 
influenced by activity levels, the rhythms occur even when measured in windows of time when 
the mice were inactive. As measured by telemetry, diurnal and circadian rhythms in HR are 
disrupted in the BACHD, Q175, R6/1 lines of mice [10,13,14,41]. For example, the Q175 
exhibited highly pronounced tachycardia during their normal sleep time, with high HR and 
reduced amplitude in the HR rhythm (Fig 1.4). Besides, the normal strong correlation between 
activity and HR, which is mediated by the ANS, was dramatically reduced in the mutants. These 
changes suggest that ANS disruption occurs early in disease progression in the Q175 line. In 
agreement, we also saw evidence in the BACHD of the circadian system failing to lower BP 
during sleep [29]. The HR rhythm in R6/1 mice are disrupted with the mutants showing a higher 
HR than WT littermates as young adults but ultimately exhibiting low HR [41]. In two other 
models (R6/2 and HdhQ150 lines), the HR was significantly reduced in symptomatic mice [46]. 
Therefore, overlapping data from several studies using different mouse models all found 
evidence for disrupted diurnal or circadian rhythms of HR.   
As far as we know, the question of whether the rhythms in HR and BP are disrupted have not 
been examined in HD patients. The preclinical data suggest that the disruptions are most likely to 
occur at the beginning of the sleep and can be difficult to diagnosis. Office visits are unlikely to 
coincide with the expression of the hypertension. This type of “masked” or nocturnal 
hypertension is associated with poor clinical outcomes as the symptoms are likely to be untreated 
and patients frequently develop organ damage prior to transitioning to sustained hypertension 
which can be detected [47,48]. Based on the preclinical data, HD patients should be strong 
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candidates for 24-hr BP monitoring which is the best method for uncovering this type of 
hypertension.   
 
Possible mechanisms underlying the dysautonomia 
The circuits involved in the generation of rhythms in HR and autonomic function are relatively 
well defined. The central circadian clock in the suprachiasmatic nucleus (SCN) orchestrates the 
peripheral clocks via ANS [49–53]. Complete separation between pre-sympathetic and pre-
parasympathetic neurons starts from the SCN (Fig 1.5) [53,54]. These separate pre-sympathetic 
and pre-parasympathetic neurons project to the paraventricular nucleus (PVN) and its separated 
pre-autonomic neurons have projections to either the preganglionic sympathetic neurons in the 
intermediolateral (IML) column of the spinal cord or the preganglionic neurons of the dorsal 
motor nucleus of the vagus (DMV). There are axon collaterals of the pre-sympathetic PVN 
neurons in the nucleus tractus solitarius (NTS). Particularly, the SCN utilizes completely 
separated sympathetic and parasympathetic neurons to convey the circadian information to the 
periphery including the heart, liver and adrenal gland. Various neuroendocrine and autonomic 
neurons are located in the PVN. Appropriate hormonal and autonomic responses are coordinated 
by the PVN [53,54].   
 
HD is a neurodegenerative disease so the most obvious cause of dysautonomia is the loss of cell 
populations in the hypothalamus or brain stem. We examined possible anatomical changes 
within the SCN of the BACHD mouse at 3 months of age just as the motor symptoms can first be 
measured. We found that the male, but not the female, SCN was smaller than WT controls. There 
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were no differences in peptide expression (arginine vasopressin, AVP; vasoactive intestinal 
peptide, VIP) within the SCN with genotype or sex. In the more severely impacted R6/2 mice, 
the SCN shows decreased expression of VIP and its receptor, VPAC2 [55]. The SCN sends 
projections out to regulate the temporal patterns of activity in several major arousal centers 
including the orexin expressing cell population in the lateral hypothalamus. The expression 
levels of orexin and AVP are reduced in HD models (e.g., [56,57]). Changes in the expression of 
brain-derived neurotrophic factor (BDNF) have also been observed. Expression of BDNF is 
normally high in the brainstem where this neuromodulator plays a crucial for regulating HR [58–
60]. The levels of BDNF are known to be reduced in the brainstem of mutant mice and resorting 
BDNF level can ameliorate HD pathology and prolong the lifespan in HD mice [61]. 
Importantly, restoring BDNF levels also returned the HR of the HD mice to the control levels 
[62]. So in the mouse models, HD alters the expression of peptides and neuromodulators in the 
brain regions involved in the neural regulation of cardiovascular function without necessarily 
causing a significant loss of hypothalamic neurons. 
 
In HD patients, there is evidence that the disease causes similar changes in expression as well as 
degeneration in the brain regions involved in the CNS regulation of cardiovascular function. In 
the hypothalamus, there is evidence for the reduction in the expression of orexin and AVP in the 
brains of the HD patients [63,64]. In addition, the levels of BDNF and its receptors (TrkB) are 
reduced in HD patients [65], and the HD aggregates directly interfere with the transcription of 
BDNF [66]. Finally, there is evidence for degeneration in the brainstem nuclei in HD patients 
including loss of neurons in the substantia nigra, pontine nuclei, reticulotegmental nucleus of the 
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pons, superior and inferior olives [67]. This study also reported the strong expression of p62 
immunopositive protein aggregates in axons of brainstem fiber tracts including the vagal nerve 
and the nucleus of the solitary tract. These structures are centrally involved in the CNS 
regulation of the CV system. Thus, by the end of life, HD certainly impacts the brain regions 
responsible for the CNS regulation of CV function and establishes a possible structural cause for 
this dysfunction. 
 
Altered SCN-driven physiology output in HD  
The circadian system is composed of cell-autonomous clock gene expression rhythms that are 
synchronized and adaptively phase aligned in tissues throughout the body by a rhythmic output 
from the SCN [68]. Individual SCN neurons express rhythms in spontaneous firing rate, with 
high firing rates observed during the day and low rates at night [69,70]. The BACHD and Q175 
mouse models of HD exhibit decreased electrical activity in the SCN during the day [10,71]. 
This decrease in daytime firing in the SCN was not seen in the R6/2 model [72] although firing 
rate deficits were seen in an SCN-driven output in the orexin neurons [57]. Using 
electrophysiological techniques, we found that SCN neural activity rhythms were lost early in the 
disease progression and were accompanied by loss of the normal daily variation in resting 
membrane potential in the mutant SCN neurons [71]. The low neural activity could be transiently 
reversed by direct current injection thus demonstrating that the neurons have the capacity to 
discharge at WT levels. Exploring the potassium currents known to regulate the electrical 
activity of SCN neurons, our most striking finding was that these cells in the mutants exhibited 
an enhancement in the large-conductance calcium- and voltage-activated potassium (BK) 
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currents. The expression of the pore-forming subunit (Kcnma1) of the BK channel was higher in 
the mutant SCN. These findings demonstrate that SCN neurons of both BACHD and Q175 HD 
models exhibit early pathophysiology and that dysregulation of BK current may be responsible.   
 
Circadian molecular feedback loop may be impacted by HD.     
The rhythms in neural activity in the SCN are driven by cell autonomous molecular feedback 
loops. At a molecular level, circadian rhythms are generated by the intracellular 
transcriptional/translational feedback loop, driving daily oscillations with a period of 
approximately 24-hrs in the expression of core clock proteins. CLOCK (Circadian Locomotor 
Output Cycles Kaput) and BMAL1 (Brain and muscle aryl-hydrocarbon receptor nuclear 
translocator-like 1) the positive components of the clock bind to E-box sequences and drive the 
expression of the negative elements period (Per) and cryptochrome (Cry) which can inhibit their 
own transcription by repressing the CLOCK/BMAL1 heterodimer. Once the levels of PER and 
CRY are decreased, the new cycle of transcription/translation is started by CLOCK-BMAL1. 
This feedback loop constitutes a 24-hr period of the internal circadian rhythms. The circadian 
nuclear receptor, Rev-erba and a retinoic acid-related orphan receptor (ROR) regulate the Bmal1 
expression via activation and repression, respectively. Post-translational modifications are 
crucial for regulating the clock. Casein kinase 1 (CK1) phosphorylate PER and CRY which is 
vital for the circadian cycle length. The expression of other clock-controlled genes and output 
genes is modulated by the CLOCK/BMAL1 heterodimer, which involving many physiological 
functions [73]. We found that the circadian rhythms in PER2-driven bioluminescence were not 
altered in the SCN in the BACHD [74]; however, deficits in gene expression rhythms were found 
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in the SCN of the more severely impacted R6/2 model [25]. Thus the evidence that the molecular 
circadian clockwork is disrupted is so far mixed, and more work is required to identify at what 
age in the disease progression these disruptions occur.     
 
These molecular rhythms are not just expressed in the SCN and work done in the R6/2 model 
clearly demonstrates that circadian rhythms of clock-driven genes that are critical metabolic 
outputs in the liver are abolished in vivo [75].  This deficiency is accompanied by arrhythmic 
expression of the clock genes Cry1 and Dbp, and a phase-advanced Per2 cycle. There is 
overwhelming evidence that circadian clock genes including Bmal1, Clock, Rev-erba, Per 1, Per 
2, Cry1, and Cry2 are rhythmically expressed in cardiomyocytes [76,77]. Functionally this 
timing system has a major impact on the expression of the genes involved in cardiac metabolism 
and electrical activity display circadian expression. For example, the metabolic genes, pyruvate 
dehydrogenase kinase 4 (pdk4) and uncoupling protein 3 (ucp3), are known to be regulated by 
peroxisome proliferator activated receptor alpha (PPARα). PPARα displays a robust rhythmic 
expression in the heart and is also shown to modulate Bmal1 by directly binding to the Bmal1 
promoter [78]. Daily oscillations of the expression in Pdk4 and ucp3 are associated with 
oscillations in the clock gene expression with the peak during the active phase. Glucose levels 
are shown to exhibit diurnal rhythms. Glucose transporters 1 and 4 (Glut1,4) have a peak in the 
expression level at the same time, suggesting increased glucose transport and utilization at the 
same time with diurnal variations. Potassium channels, Kv1.5 and Kv4.2, as well as calcium 
transients show rhythmicity in the protein expression levels [79].  
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There is still much work to do to understand how the molecular clock controlling transcription 
interacts with the physiology of CV function. The general assumption is that the temporal pattern 
of transcription favors ATP production and energy utilization during the active phase while 
allowing remodeling and repair to dominate during rest. One particularly interesting case study 
involves the rhythmically expressed kruppel-like factor 15 (KLF15).  Depletion of KLF15 in 
cardiomyocytes leads to a disorganized circadian behavior despite an intact core clock [80]. 
KLF15 transcriptionally controls the rhythmic expression of Kv channel-interacting protein 2, a 
critical subunit required for generating a transient potassium current. Deficiency or excess of 
KLF15 causes loss of rhythmic QT variation, abnormal repolarization and enhanced 
susceptibility to ventricular arrhythmias [81]. We do not know whether the HD mutation impacts 
KLF15 or other critical rhythmic outputs. We consider this lack of knowledge a major hole in the 
literature as HD-driven alterations in circadian output could be an important clinical symptom of 
the disease.    
 
Genetic or environmental disruption of the circadian timing system leads to CV symptoms 
Regardless of the specific cause, prior work has shown that the genetic or environmental 
disruption in circadian rhythms can result in CV symptoms. For example, mice held in a 20-hr 
(LD10:10) cycle are exhibited worse cardiac damage in response to high BP compared to 
controls held on a normal 24-hr cycle (LD 12:12) [82]. These lighting conditions alter rhythms in 
clock gene expression in both the heart and brain. Furthermore, “tau” mutant hamsters have a 
mutation in CK1 which results in a short endogenous cycle length of approximately 22-hrs [83] 
and, when they are held under a 24-hr LD cycle, these mutant hamsters die early with 
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cardiomyopathy including fibrosis[83]. However, when the mutant hamsters are housed in a 22-
hr LD cycle or are made arrhythmic by destruction of their circadian clock (SCN), the hamsters 
are protected from developing cardiac dysfunction [83]. These results suggest that discord 
between the internal circadian clock (22 hrs) and external environment (24 hrs) can trigger 
cardiac disease. To provide a final example, Bmal1-knock out (KO) mice exhibit arrhythmic 
circadian behavior, age-related dilated cardiomyopathy, and shorten life span [84–87]. These 
symptoms are also seen in the cardiomyocyte-specific Bmal1 KO mice [88]. To understand the 
role of circadian clock within the cardiomyocyte on myocardial biology, a cardiomyocyte-
specific Clock mutant (CCM) mouse model was assessed [89,90]. CCM mice show decreased 
diurnal rhythms in HR, reduced cardiac efficiency, and bradycardia [89]. The cardiac 
hypertrophic markers are elevated in CCM mice [90]. These data suggest an essential role of 
cardiomyocyte circadian clock in CV function and highlight the possibility that at least some of 
the CV symptoms seen in HD could be the consequence of the well-established circadian 
dysfunction.  
 
Finally, sleep disruption and work schedules that disrupt the circadian system are also risk 
factors for CV disease in humans [45]. Epidemiological studies show that approximately 40% of 
the population in North America do not get the recommended amount of sleep, and the reduced 
sleep duration is associated with a high risk of cardiac disease [91]. In the laboratory, placing 
healthy adults in an inverted sleep/wake and meal cycle for three days is sufficient to increase 
their BP and levels of the inflammatory markers [92]. A short 2 hr disruption of the sleep/wake 
can increase resting HR and cortisol levels in healthy subjects [93]. The sleep and rhythms 
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disruption due to work schedule is associated with the adverse endocrine and CV profiles in 
subjects, putting them at increased CV risk [93]. In a study performed on healthy male shift 
workers, 24-hr electrocardiogram recordings are used to investigate the effect of the work 
schedule on the cardiac autonomic control [94]. Results show a reduction in the cardiac 
sympathetic modulation based on the HRV analysis, suggesting an increased risk for CV events 
[94]. Therefore, the data from humans is consistent with our assertion that the sleep and 
circadian dysfunction seen in HD could contribute to the CV symptoms seen in the patients.  
 
Conclusions and outlook: 
 
The body of evidence presented in this review is consistent with the hypothesis that the 
disruption of the SCN circuit contributes to the autonomic dysfunction seen in HD. If correct, 
this hypothesis has a number of predictions. First, the normal diurnal and circadian rhythms in 
HR and BP driven by the ANS will be disrupted in HD. To date, the disrupted rhythms in HR, 
BP and baroreceptor reflex from data in HD animal models and patients support this hypothesis. 
Second, removing the mutant Htt from the heart will not be sufficient to rescue cardiac function. 
In contrast, reducing Htt in the brain will be sufficient, and specifically the CNS circuit 
controlling autonomic function will be a critical target. This prediction is clinically important as 
a number of clinical trials with mHtt lowering agents are ongoing. Third, treatment with drugs 
focusing on dysautonomia should be targeted to specific times of the daily cycle. For example, 
beta-adrenergic receptor blockers may produce the most substantial benefits when taken before 
bed. Fourth, cardiac function shows a robust diurnal variation including rhythms in HR and BP. 
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This body of preclinical data described in this review suggests that monitoring of the 
cardiovascular system in HD patients should start at an early age so therapeutic interventions can 
be employed to slow the progression of these pathological processes and prevent early death. 
Most importantly, our data suggest that this early screening must include observations during the 
usual sleep hours of the day, as early anomalies may go undetected at the times of day that 
patients would usually interact with clinicians. Finally, we predict that treatments or lifestyle 
changes that improve the circadian timing system will reduce the autonomic dysfunction in HD. 
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Chapter 2: Cardiovascular dysfunction in the Huntington’s Disease models, Q175 and BACHD 
 
Introduction: 
Over the course of a lifetime, Huntington’s disease (HD) patients are subject to a progressive 
neurodegenerative process that inflicts cognitive, psychiatric and motor dysfunction [1,95]. HD 
is caused by a CAG repeat expansion within the first exon of the huntingtin (Htt) gene and when 
translated, produces a polyglutamine (polyQ) repeat that leads to protein misfolding, soluble 
aggregates, and inclusion bodies detected throughout the body [3,4]. The normal function of the 
protein (HTT) is unknown; however, the mutated form leads to dysfunction of a large range of 
cellular processes including cytoskeletal organization, protein folding, metabolism and 
transcriptional activities. Cardiovascular events are a major cause of early death in the HD 
population and these events occur at higher rates compared to the rest of the population 
[6,96,97]. The limited cardiovascular studies in HD patients attribute the increased 
cardiovascular susceptibility in part to a dysfunctional autonomic nervous system (ANS) that can 
be detected early in the disease progression [18–22,30]. Additional studies are needed to better 
understand the time-course and cause of cardiovascular pathology in HD that could potentially 
help improve symptoms and prevent early death. 
 
While there is no perfect animal model of HD [5], several models recapitulate aspects of the 
cardiovascular dysfunction seen in human disease. For example, dysfunction of the ANS has 
been reported in the several mouse models of HD as measured by heart rate variability and 
baroreceptor reflex experiments [10,29,41,46]. Reduced contractility and cardiac output is also a 
  
19  
common feature in mouse models [9–12,29]. The cardiac-specific expression of polyQ repeats 
leads to dysfunction, suggesting that cardiovascular disease is a result of both local dysfunction 
as well as improper input [16,17]. Advances in these preclinical models are critical if we are to 
develop a mechanistic understanding of the cardiovascular pathology in HD but establish models 
to evaluate therapeutic interventions. 
In this chapter, we focus on examining possible cardiovascular dysfunction in the Q175 model of 
HD.  The heterozygote (Het) Q175 offers advantages including: a single copy of the mutation, 
genetic precision of the insertion and control of mutation copy number [98,99]. These features 
make the Het Q175 line perhaps the most clinically relevant among the animal models; however, 
possible autonomic dysfunction has not been examined. We sought to test the dual hypotheses 
that cardiovascular dysautonomia can be detected early in disease progression in the Q175 model 
and that this dysfunction varies with the daily cycle. We used radiotelemetry to assess diurnal 
and circadian rhythms in activity, core body temperature (CBT), and heart rate (HR) in young 
(3–4 months of age) and middle aged (9–10 months of age) Q175 and wild-type (WT) mice. To 
further explore possible autonomic dysfunction, we measured HRV throughout the 24-h cycle as 
well as the baroreceptor reflex during the normal rest cycle. In addition, we evaluated the age-
dependent progression in heart dysfunction in a separate cohort of mice using echocardiograms 
starting at 3 months of age and progressing to 12 months of age when the motor symptoms are 
pronounced and brain atrophy can be detected. Tissue was then collected to examine 
histoanatomical features of the Q175 hearts. 
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In addition, we sought to confirm some of our findings with the Q175 using the better studied 
BACHD line.  Specifically, using this disease model, we evaluated the age-dependent 
progression in heart dysfunction using echocardiograms starting at the beginning of motor 
symptoms at 3 mo of age and progressing to an age (15 mo) when the motor symptoms are 
pronounced and brain atrophy can be detected. In addition, we examined gene expression 
profiles in the heart early (3 mo) and late (15 mo) in the disease progression in the BACHD 
model.   
 
 
Methods: 
 
Experimental Animals and Ethics Statement 
BACHD mice on the C57BL6/J background along with littermate wild-type (WT) controls were 
acquired from the mouse mutant resource at The Jackson Laboratory, (JAX, Bar Harbor, Maine) 
in a colony maintained by the CHDI Foundation. The mice start showing symptoms at 2–3 mo of 
age and by 12 mo manifest full symptoms. In our colony, the BACHD mice commonly live to 18 
mo of age but their health declines precipitously after 16 mo. Therefore, we stopped the present 
study when mice reached 15 mo of age. Five separate cohorts of mice of each genotype were 
used for this study: 1) longitudinal measurement of cardiac function using echocardiograms; 2) 
chronic treatment with isoproterenol (ISO) to boost cardiac output from 3 to 6 mo of age; 3) 
transcriptional comparison between the hearts of genotypes at 3 and 15 mo 
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of age; 4) measurement of serum cytokines in 3 mo old animals using a multiplex assay; 5) 
measurement of an apoptotic marker in 12–15 mo hearts by western blot.  
Homozygous (Hom) and Het Q175 mice on the C57BL6/J background along with littermate WT 
controls were acquired from the mouse-mutant resource at The Jackson Laboratory, (JAX, Bar 
Harbor, Maine; stock No: 370476). The mice are full backcrossed into the C57 line (>12 crosses) 
and are monitored for the number of CAG repeats (approximately 190). Het Q175 mice 
commonly live to 24 months of age but the health of the Hom Q175 declines precipitously after 
16 months. Therefore, we stopped this study well before this age point. Three separate cohorts of 
mice of each genotype were used for this study: (1) Telemetry studies measuring activity, CBT 
and electrocardiograms (ECG). Recordings (6–8 weeks in duration) were made from mice in a 
light-dark (LD) cycle as well as in constant darkness (DD) starting when the mice were 3 months 
and then again at 9 months of age; (2) Baroreceptor reflex measurements at 9 months of age; (3) 
longitudinal measurement of cardiac function using echocardiograms with measurements made 
at 3, 6, 9 and 12 months. The hearts of this third cohort of mice were then used for histological 
analysis. The LD cycle consisted of 12 h of light and 12 h of dark. By convention, the time of 
lights-on being defined as zeitgeber time zero (ZT 0). By convention, when the mice were held 
in DD, the beginning of activity onset is defined at circadian time zero (CT 0). 
 
All procedures followed guidelines of the National Institutes of Health and were approved by the 
UCLA Animal Research Committee. To provide some details, the health of the mice was 
monitored daily. We looked for a set of symptoms including restlessness, impaired mobility, 
licking or guarding wound, failure to groom, open sores, loss of appetite or weight loss. At any 
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sign of ill health, a member of the veterinary staff was consulted for the course of treatment. If 
the animal did not improve, then it would be humanely sacrificed with an overdose of isoflurane 
and followed by decapitation. For pain management, the mice were given carprofen at 5 mg/kg 
every 24 hrs for 48 hr minimum. The first dose was given before surgery, and the remaining 
post-operatively. 
 
Telemetry measurements 
Methods employed were similar to those previously described [10,13]. WT, Hom Q175, and Het 
Q175 mice (n = 10 per genotype) were surgically implanted with a wireless radio-frequency 
transmitter (ETA-F20, Data Sciences International, St. Paul, MN). Three of the WT mice and 
one of the Hom Q175 did not exhibit measurable signals and had to be excluded from the final 
analysis. Mice were housed in individual cages in the absence of a running wheel. Cages were 
placed atop telemetry receivers (Data Sciences International) in a light and temperature-
controlled chamber. Standard rodent chow was provided ad libitum. Data collection began 2-
weeks postsurgery, to allow mice to recover in the 12:12 LD cycle. HR is extrapolated from 
ECG waveforms using the RR interval. All measurements were made in both LD and DD 
conditions at 3 months (young) and 9 months (middle age). At each age, the recordings took 6–
8 weeks to complete. Cage activity in DD was also examined by periodogram analysis 
(ClockLab program, Actimetrics, Wilmette, IL) to estimate the free-running period.  
 
Echocardiograms 
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WT (n = 10) and BACHD mice (n = 10) were group housed and kept in a 12:12 light/dark (LD) 
cycle with rodent chow provided ad libitum. Mice were examined with echocardiograms at 3, 6, 
9, 12 and 15 mo of age. After the last echocardiogram measure, the mice were perfused and 
morphologic and histological measurements were taken. During the course of the study, 1 
BACHD and 2WT mice died and the data from these mice were excluded from the analysis.  
 
WT (n = 12), Q175 Het (n = 10) and Q175 Hom mice (n = 10) were group housed and kept in a 
12:12 LD cycle with rodent chow provided ad libitum. Mice were examined with 
echocardiograms at 3, 6, 9, 12 months of age. After the final measurement, the mice were 
perfused and morphological and histological measurements of the heart were taken. 
 
WT (n = 8), BACHD (n = 8), and BMYO mice (n = 8) were group housed and kept in a 12:12 
light/dark (LD) cycle with rodent chow provided ad libitum. Mice were examined with 
echocardiograms at 3 and 6 mo of age. After the last echocardiogram measure, the heart and 
brain tissues of the mice were collected and morphologic and histological measurements were 
taken.  
 
Echocardiograms were measured using a Siemens Acuson Sequoia C256 instrument equipped 
with a 15L8 15MHz probe (Siemens Medical Solutions, Mountain View, CA) as previously 
described. Briefly, two-dimensional, M-mode echocardiography and spectral Doppler images 
enabled measurement of heart dimension and function (Left Ventricle (Lv) Mass), end-diastolic 
dimension (EDD), end-systolic dimension (ESD), posterior wall thickness (PWT), ventricular 
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septal thickness (VST), Lv Ejection Fraction (Lv EF). The mice were sedated with 1% isoflurane 
vaporized in oxygen (Summit Anesthesia Solutions, Bend, OR) and HR was monitored using 
electrocardiogram to maintain physiological levels (between 450 and 650). 
 
Isoproterenol (ISO) Treatment 
BACHD and WT mice (2–3 mo) were subjected to echocardiograms before subcutaneous 
implantation of an osmotic pump (Alzet model 2001, Durect Corp, Cupertino, CA) containing 
either saline (WT: n = 4; BACHD: n = 4) or ISO (WT: n = 10; BACHD: n = 8). To determine an 
effective dose of isoproterenol, each treated mouse received sequentially increased doses of ISO, 
beginning with 0.24 mg/day, then 0.48 mg/day, and finally 0.97mg/day. It was this final 
concentration that proved effective at significantly increasing HR and was used in this study. At 
the end of the treatments (3 months duration), the cardiovascular function was assessed using 
electrocardiogram recording and echocardiography. After the last echocardiogram measure, 
the mice were perfused and morphologic and histological measurements were taken. 
 
Electrocardiogram (ECG) Measurements 
ECG traces were obtained under isoflurane anesthesia by inserting two platinum needle 
electrodes (Grass Technologies, West Warwick, RI) under the skin in the lead II configuration. 
The ECG signal was amplified (Grass Technologies), acquired and analyzed with HEM V4.2 
software (Notocord Systems, Croissy sur Seine, France). The ECG data were recorded for 5 to 
10 mins from each mouse monthly for the duration of the study. Heart rate (HR) was calculated 
using the RR-interval for all animals. 
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Heart Rate Variability  
Data were extracted in 20-sec intervals then filtered to remove extreme noise. Remaining valid 
data segments were averaged into 1 h bins across the 24-h cycle. The following parameters for 
time domain analysis were calculated: mean normal-to-normal intervals (NN, in msec) and, 
standard deviation of all NN intervals (SDNN, in msec). For frequency domain analysis, spectra 
were calculated with a FFT (fast Fourier transform) with 20,000 data points per bin and a 
periodogram resolution of 8192, three overlapping subseries and a Hamming window (HRV 
Module, Data Sciences International). Frequency bins were defined as high-frequency (HF 1.5–
5.0 Hz), low-frequency (LF: 0.2–1.5 Hz) and very low frequency (VLF: 0.01–0.2 Hz), and the 
power in these bands was calculated [100,101]. While it is common for LF and HF to be 
expressed in normalized units, this normalization minimizes the circadian regulation that we are 
interested in examining [102]. Therefore, we reported the raw LF and HF values (mV/Hz).  
 
Baroreceptor reflex 
Methods employed were similar to those described previously [29]. The administration of 
angiotensin II (ATII) or nitroprusside (NP) triggers acute hypertension or hypotension, 
respectively. Changes in blood pressure (BP) as a result of administering these drugs should 
elicit a compensatory response of HR. Differences in the ratio of change in HR to BP 
(∆HR/∆BP) are suggestive of aberrant signaling to the heart by the ANS. Baroreceptor function 
was examined during the day (ZT4-9) in middle age (9 months) mice of each genotype: WT 
(n = 8), Hom Q175 (n = 10) and Het Q175 (n = 8). These measurements took 4 weeks to 
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complete. The procedure was unsuccessful in some of the mice (WT, n = 1; Het Q175, n = 2; 
Hom Q175, n = 1) and data could not be used. During the experiment, HR was determined from 
the R-R interval of the ECG. Mice were anesthetized and both femoral arteries were catheterized, 
whereby BP measurements were collected from one artery and drugs were administered through 
the other artery. Following catheterization, isoflurane levels were decreased to between 1 and 
1.5% and the mice were allowed to rest for at least 10 min. Baseline BP and HR were then 
recorded. AT II (4.0 µg/kg) and NP (40 µg/kg) were administered in sequence to probe the HR 
response to the changes in BP. Each treatment was followed by a flush of saline (+heparin 
3 U/mL) to ensure full delivery of the drugs. As a control, muscarinic (75 µg/kg glycopyrrolate) 
and β-adrenergic (750 µg/kg propranolol) receptors were blocked before administering another 
dose of ATII or NP. The absolute value of the maximum change in BP as well as the subsequent 
directional change in HR was determined. Ratios of these two values (∆HR/∆BP) reflected the 
magnitude HR change relative to the change in BP that characterizes the sensitivity of the 
baroreceptor response.  
 
Morphometry and Histology 
Following the longitudinal echocardiogram measurements as well as the ISO treatments 
(described above), animals were deeply anaesthetized using isoflurane and perfused with 
phosphate-buffered saline (PBS, pH 7.4) with heparin (2 units/ml, Henry Schein, Melville, NY) 
followed by 4% (w/v) paraformaldehyde (Sigma-Aldrich) in PBS (pH 7.4). A motorized pump 
was used to deliver the solutions in order to control and maintain similar pressure between 
animals. Hearts were dissected, weighed and post-fixed at 4°C. Tibia length (TL) was also 
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measured. Heart weight (HW)/TL and HW/body weight (BW) ratios were calculated to 
determine any differences in morphometry that would indicate cardiac hypertrophy. Following a 
series of dehydration steps using ethanol and xylene, hearts were embedded in paraffin. Paraffin-
embedded hearts were sectioned and stained with H&E or Masson’s Trichrome. Heart 
dimensions were measured using two mid-ventricular cross sections from each H&E and/or 
Masson’s Trichrome-stained heart with the aid of Image J software. The presence or absence of 
fibrotic staining was visually scored by two researchers masked to the experimental conditions. 
In order to quantitate the degree of fibrosis, images were acquired from each heart. Areas of 
fibrosis were captured, and in sections lacking positive fibrotic staining, an area of the left 
ventricle (Lv) wall was imaged. Pictures were processed using Corel Draw, to remove pixels of 
background and pink cardiomyocyte tissue, leaving areas of positive blue stain in the image. 
Integrated density of these processed images was measured using Image J, where pixel areas less 
than 3 were excluded from the measurements in order to minimize noise. The resulting density 
numbers were divided by the area of the heart tissue in the image. 
Trichrome stained sections were used to estimate the cardiomyocyte cross-sectional area in aged 
(15 mo) WT and BACHD mice (n = 4 per group). Measurements were performed by three 
observers masked to the genotype of the mice. Images from multiple fields (3–5) at the level of 
the papillary muscles were acquired on a Zeiss Axioskop with an Axiocam using the AxioVision 
software (Zeiss, Pleas- anton, CA, USA), and measurements (in µm) obtained using the 
AxioVision software. Only cells with a well-defined round shape were considered. The cross-
sectional areas of 7–12 cells/animal were averaged and analyzed for the statistical difference. 
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Two mid-ventricular-stained cross sections were used to obtain morphometric measurements and 
to estimate the number of fibrotic areas in WT (n = 5), Hom and Het Q175 mice (both n = 6 per 
genotype). Images of the mid-ventricular cross sections from each heart were acquired on a Zeiss 
Stereomicroscope (Stemi SV 11 Apo) equipped with an Axiocam using the AxioVision software 
(Carl Zeiss). Measurements were performed by two observers masked to the genotype of the 
mice using the Zeiss Axiovision software. The thickness of the left ventricular wall was 
measured in three different nonseptal parts to obtain an average thickness. Values from the two 
sections were averaged. Fibrotic areas, suggestive of necrotic areas, that is, infarcts, were 
visually identified and counted by three observers masked to the genotype on a Zeiss Axioskop 
(Carl Zeiss, Pleasanton, CA). To determine which chamber or part of the interventricular septum 
was more affected, the locations of the infarctions in the heart were also annotated.  
 
For wheat germ agglutinin (WGA) staining, deparaffinized sections were rehydrated through an 
alcohol gradient starting at 95% ethanol to 50%. Heat-induced antigen retrieval was performed 
using 10 mmol/L Citrate buffer (pH 6.0), followed by blocking in 10% BSA/PBS for 1 h. Slides 
were incubated with Alexa Fluor 594-WGA (50 µg/mL, 10 min, Invitrogen) in PBS and mounted 
using ProLong Gold (Invitrogen, Carlsbad, CA). Confocal images of stained sections at the 
levels of the papillary muscles were captured, using a confocal scanning microscope (Nikon, 
Melville, NY) and the cross-sectional area of the cardiomyocytes was measured using the NIS 
Elements (Nikon) software (50-100 cells from 6 to 8 areas per mouse heart, n = 6 per genotype).  
 
RNA Extraction 
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A separate cohort of young (3 mo) and older (15 mo) WT and BACHD mice (n = 4 per group) 
were used for gene expression analysis. Total RNA from the ventricles were extracted using 
Trizol RNA isolation protocol (LifeTechnologies, Carlsbad, CA), then DNAse treated (TURBO 
DNA-free kit, Life Technologies) and column purified (Pureline RNA Mini-kit, Life 
Technologies). RNA was used for microarray and Quantitative Real-Time PCR experiments 
described below. 
 
Microarray Hybridization 
Microarray processing was performed by the Southern California Genotyping Consortium at 
UCLA. Briefly, whole genome gene expression profiling protocols began with 100 ng of total 
RNA isolated as described above. Samples were quantitated using Ribogreen fluorescent assay 
and normalized to10 ng/ul prior to amplification. Amplified and labeled cRNA was produced 
using the Illumina-specific Ambion TotalPrep kit. 1st and 2nd strand cDNA was produced using 
the Ambion kit (Life Technology) and purified using a robotic-assisted magnetic capture step. 
Biotinylated cRNA was produced from the cDNA template in a reverse transcription reaction. 
After a second Ribogreen quant and normalization step, amplified and labeled cRNA was 
hybridized overnight at 58°C to Illumina MouseRef-8 v2.0 expression arrays. Hybridization was 
followed by washing, blocking, staining and drying on a Little Dipper processor. Array chips 
were scanned using an iScan reader, and expression data were extracted and compiled using 
BeadStudio software (Illumina, San Diego, CA). 
 
Quantitative Real-Time PCR 
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One µg of total RNA was reverse transcribed using High Capacity cDNA Reverse Transcription 
Kit (Applied Biosystems, Foster City, CA). Quantitative real-time RT-PCR was performed using 
SYBR Green Mix (Applied Biosystems, Foster City, CA). Using Primer3 [103] following 
primers were designed to flank intron-exon broundaries: Hspa1a (sense: 5’-GGT CTC AAG 
GGC AAG CTC AG-3’ and anti-sense: 5’-CTT GTG CAC GAA CTC CTC CT-3’) Nppb (sense: 
5’-TCC TCT GGG AAG TCC TAG CC-3’ and anti-sense: 5’-AGC TGT CTC TGG GCC ATT 
TC-3’) Kcnip2 (sense: 5’-AAT CCC GAG ATT TGG ACG GC-3’ and antisense: 5’-GCT TGA 
GGA AAC GCT GCT TC-3’) Acot1 (sense: 5’-AGA AGC CGT GAA CTA CCT GC-3’ and 
antisense: 5’-GGA AGG AGG CCA TAG CAA GG-3’) Tbp (sense: 5’ CAC GGA CAA CTG 
CGT TGA TT-3’ and antisense: 5’-AGC CCA ACT TCT GCA CAA CT-3’) B2M (sense: 5’-
GGT GAC CCT GGT CTT TCT GG-3’ and antisense: 5’-TGT TCG GCT TCC CAT TCT CC-
3’). Specificity and efficiency of the reactions were verified using melting curves and dilution 
series, respectively. Expression levels of Hspa1a, Nppb, Kcnip2, and Acot1 were calculated 
using the 2-ΔΔCt method where Tbp and B2m were used as normalizing genes. Tbp and B2m did 
not vary between genotypes and we report gene expression normalized to Tbp. 
 
Multiplex Assay 
Blood sample was collected from a separate cohort of young (3-4mo) WT (n = 8) and BACHD 
(n = 8) mice using the facial vein technique. Blood was allowed to clot for at least 30 mins at 
room temperature, and serum was collected following centrifugation at 3000rpm for 15 mins and 
frozen at -80C until analyzed. A volume of 25µL serum was used to assess cytokine levels of 
IFNγ, IL-10, IL-12, IL-1A, IL-1B, IL-2, MIP1A, RANTES, IL-6, MCP-1, and TNF-α using the 
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Millipore cytokine milliplex kit (EMD Millipore Corporation, Billerica, MA, USA) and the 
Biorad Bio-plex 200 systems machine (Hercules, CA, USA). 
 
Western Blot 
Hearts from aged WT (n = 4) and BACHD (n = 4) mice were rapidly dissected and homogenized 
in lysis buffer containing 50 mM Tris/HCl, 0.25% (w/v) DOC (sodium deoxycholate), 150 mM 
NaCl, 1 mM EDTA, 1nM EGTA, 1% (w/v) Nonidet P40, 1 mM Na3VO4 (sodium 
orthovanadate), 1 mM AEBSF [4-(2-aminoethyl)benzenesulfonyl fluoride], 10 µg/ml aprotinin, 
10 µg/ml leupeptin, 10 µg/ml pepstatin and 4 µM sodium fluoride. Total protein concentration in 
cleared extracts was estimated using the Thermo Scientific™ Pierce™ BCA Protein Assay Kit 
(Thermo Fisher Scientific, Waltham, MA USA). Fifty µg of total proteins were loaded on to a 4–
20% Tris-glycine gel (Invitrogen, Carlsbad, CA). Western blots were performed as previously 
described [104]. Equal protein loading was verified by Ponceau S solution (Sigma, Saint Louis, 
MO) reversible staining of the blots. Each extract was analyzed for the relative protein levels of 
Heat-Shock protein (Hsp)-70, by using a mouse monoclonal antibody (Sigma, Saint Loius, Mo), 
and Cleaved Caspase-3, by using rabbit polyclonal antibodies (EMD Millipore Corporation, 
Billerica, MA & Cell Signaling, Danvers, MA). Each extract was also analyzed for relative 
protein levels of GAPDH (Genetex, Irvine, CA) by stripping and re-probing. Protein bands were 
detected by chemiluminescence using the Thermo Scientific™ Pierce™ ECL 2 Western Blotting 
Substrate or the Amersham ECL kit (GE Healthcare; Piscataway, NJ) with HRP (horseradish 
peroxidase)-conjugated secondary antibodies (Cell Signaling, Danvers, MA). Relative intensities 
of the protein bands were quantified by scanning densitometry using the NIH Image Software 
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(Image J, http://rsb.info.nih.gov/ij/). For the comparison of relative protein levels in the heart 
from WT and BACHD animals, each background-corrected value was normalized according to 
the relative GAPDH levels of the sample, and then referred to the average of the WT values 
calculated from the same immunoblot image. 
 
Statistical Analysis 
A two-way repeated measures ANOVA was used to analyze the long-term changes in 
echocardiographic measurements between WT and BACHD animals using genotype and age as 
factors. Other comparisons between the two genotypes were made using a Student’s t-test. If the 
data set failed to pass a test for equal variance, a Rank-Sum Test was used. These statistical 
analyses were performed using the SigmaStat (San Jose, CA) or Prism 5 (GraphPad Software, 
San Diego, CA) statistical software. Data are shown as the mean ± SEM. Raw microarray data 
were analyzed by using Bioconductor packages as previously described [105]. Briefly, quality 
assessment was performed by examining the inter-array Pearson correlation and clustering based 
on the top variant genes. Contrast analysis of differential expression was performed by using the 
LIMMA (Linear Models for Microarray and RNA-Seq Data) package [106]. After linear model 
fitting, a Bayesian estimate of differential expression was calculated, and the P -value threshold 
was set at 0.005. The fold change of gene expressions is calculated by comparing the signal 
intensity of young hearts and old hearts. Differentially expressed genes were then classified 
according to gene ontology and pathways using Ingenuity Pathway Analysis (IPA, Ingenuity 
Systems, Redwood City, CA). After applying threshold at P = 0.005, the top 10 genes up-
regulated and down-regulated in BACHD compared to WT at the same age are selected 
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according to their P-value. In other words, they are the most significantly changed genes in the 
comparison. 
 
For most of our experiments, two-way analysis of variance (ANOVA) was used to determine 
statistical significance with genotype (WT, Het Q175, Hom Q175) and time (either ZT or CT) as 
the two factors. If the data did not exhibit a normal distribution, a two-way ANOVA on ranks 
was used. Post hoc t-test with Bonferroni's corrections was applied to determine significant 
differences between genotypes at each of the hourly bins (ZT or CT). In the cases in which we 
only obtained the measurements at one age (baroreceptor, histological measurements), we used a 
one-way ANOVA followed by Bonferroni's multiple comparison test or a one-way ANOVA on 
ranks. Correlations between activity and heart rate were examined by applying the Spearman 
correlation analysis to 21,700 contiguous, 20 sec, time-matched, heart rate and activity bins per 
mouse at two ages (3 months, 9 months). R-values were then compared between groups using a 
two-way ANOVA. For a comparison of the number of infarcts, we used a Kruskal–Wallis 
ANOVA followed by Dunn's multiple comparison test. These statistical analyses were 
performed using the SigmaStat (San Jose, CA) or Prism 5 (GraphPad Software, San Diego, CA) 
statistical software. Values are reported as the mean ± Standard Error of the Mean (SEM).  
 
 
Results: 
 
Altered diurnal and circadian resting HR rhythms in the Q175 line. 
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We examined the HR when the Q175 animals were physically inactive, that is, the resting HR. 
The young Q175 exhibit abnormally high resting HR under both LD and DD, mostly during the 
late day and early night (Fig 2.1A and B). By middle age in DD, this tachycardia reversed and 
we actually saw low resting HR in the Hom Q175. The low HR in the Hom Q175 occurred 
primarily during the early subjective day (Fig 2.1C and D). The simultaneous recording of HR 
and activity allows the analysis of HR evoked by movement; hence, we measured HR when the 
animals were physically active, that is, the active HR. Again, a significant effect of genotype in 
young animals was found under both LD and DD conditions. The Hom Q175 exhibited a 
significantly increased active HR during the early day and subjective day. Similar results were 
obtained in middle aged mutants, with a significant effect of genotype under both LD and DD 
conditions. 
 
A significantly increased activity-evoked HR was observed in the Hom Q175 during the early 
day and subjective day as well as a reduced correlation between activity and HR (Fig 2.2). For 
example, in WT mice, the Spearman correlation between activity and HR was 0.56 ± 0.03 while 
in the Hom Q175 the correlation was reduced to 0.42 ± 0.02 (genotype, F = 10.4; P < 0.001). 
Finally, we compared a number of parameters of the ECG waveform (RR, PR, QRS, QT, QAT, 
MxdV) in WT and the Q175 mutants under LD conditions (Table 1). Significant differences 
between the genotypes were seen with RR, QRS, and QAT intervals. In summary, the Hom 
Q175 exhibited tachycardia during rest and activity with the high HR being most pronounced 
during the day when HR was normally low. Even in young animals, the ANS-driven rhythms in 
HR were disrupted in the Q175 line.  
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Reduced HRV in the Q175 line. 
To further explore autonomic dysfunction in the Q175 line, we measured HRV throughout the 
24-hr cycle. HRV measures the variability in the time between individual heartbeats and reflects 
the balance of the sympathetic and vagal inputs regulating heart rate. High HRV is associated 
with cardiovascular health, while low HRV is a sign of poor cardiovascular function. We 
observed high HRV during the day and lower at night (Fig 2.3A) in WT mice. Conversely, the 
HRV was abnormally low in the HD mutants (Hom, Het) and this damping was largest during 
the sleep phases. HRV measures were separated into low-frequency (LF: 0.2–1.5 Hz) and high-
frequency (HF, 1.5–5.0 Hz) bands, which are commonly used to quantify parasympathetic and 
sympathetic regulation, respectively. In WT mice, the power of both the LF and HF bands 
exhibited a daily rhythm which peaked during the night (Fig 2.3B and C). The power of the HF 
band was minimally impacted with the young Hom Q175 exhibiting significant differences only 
in the late night (Fig 2.3B). In contrast, the power of the LF band was greatly impacted 
throughout the night in the mutants (Fig 2.3C). These results demonstrate that the temporal 
patterning as well as the overall level of autonomic regulation of the cardiovascular system is 
compromised in the Q175 mice.  
 
Baroreceptor reflex is compromised in the Q175 line.   
The baroreceptor reflex is a rapid homeostatic mechanism by which perturbations in blood 
pressure are countered by change in HR mediated by the ANS. In previous work, we have shown 
that the BACHD mice show an abnormally weak baroreceptors response to decreases in blood 
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pressure, consistent with a weak sympathetic regulation of heart rate [29]. We performed 
baroreceptor evaluations to determine the autonomic responsivity to drug-induced changes in BP 
(Fig 2.4A and B). As expected, the middle-aged WT mice had normal reflex responses, that is, 
when the BP was transiently increased with angiotensin II (ATII, 4 µg/kg), the heart rate dropped 
in compensation, and when the BP was transiently lowered with nitroprusside (NP, 40 µg/kg), 
the heart rate was elevated. The effects of ATII and NP were completely blocked by pretreatment 
with sympathetic and parasympathetic receptor antagonists (750 µg/kg propranolol, 75 µg/kg 
glycopyrrolate) (Fig 2.4). Interestingly, the Hom Q175 mice had very blunted HR responses to 
NP (one-way ANOVA on ranks: H = 11.3, P = 0.004). While some of the Het Q175 (2/6) 
showed a greatly reduced response to the NP injection, the overall NP-response was not 
significantly different from the WT (Fig 2.4A). There were no significant changes in response to 
ATII injection although we did observe an abnormal instability in the Hom Q175 HR (Fig 
2.4B). Systolic BP did not significantly vary with genotype (WT: 83 ± 4 mm Hg; Het Q175: 
76 ± 4; Hom Q175: 71 ± 3; F = 2.8; P = 0.08). These data provide further evidence of 
diminished autonomic function, especially of the sympathetic branch.  
 
Echocardiograms characterize age-related decline in the Q175 and BACHD lines.   
 
The age-dependent progression in heart dysfunction of the Q175 mice was evaluated in a 
separate cohort of mice using echocardiograms beginning at 3 months of age and progressing to 
12 months (Fig 2.5D and E; Table 2). Both the cardiac structure [Lv mass, EDD, ESD] and 
function (FS%, E/A ratio, Lv EF) were significantly influenced by age and genotype (Table 3). 
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For example, the Lv mass of the Hom Q175 was significantly smaller compared to WT and Het 
Q175 by 6 months of age (Fig 2.5D). Cardiac function, measured by Lv EF, was significantly 
diminished in the Hom Q175 beginning at 9 months. Both the Hom and Het Q175 exhibited a 
reduction in this parameter compared to WT at 12 months (Fig 2.5E). By 9 months of age, the 
hearts of Hom Q175 mice were smaller and functionally depressed compared to WTs.  
 
We assessed cardiac structure and function in a group of BACHD and WT mice throughout most 
of their adult life in order to follow changes in cardiovascular parameters and establish a time 
course for pathology. We use echocardiography to follow the same BACHD and WT littermate 
control mice longitudinally from 3 to 15 mo (Fig 2.5A-C; Table 4). The hearts of WT mice 
slowly increased in dimension as they aged, with significance in EDD and PWT starting at 12 
mo while Lv Mass and ESD were significantly larger at 15mo (Fig 2.5A and B; Table 4). 
Cardiac function as measured by Lv EF showed an increase between 3 and 6 mo as is typical 
with development of WT mice and then declined with age (Fig 2.5C). The hearts of BACHD 
mice also increased in size as they aged, with a significant increase in Lv Mass and PWT 
measures starting at 9 mo of age (Fig 2.5A; Table 4). Cardiac function of BACHD mice did not 
significantly change with age (Fig 2.5C; Table 4). The hearts of BACHD mice were larger (ESD 
and EDD) and thicker (PWT) than WT mice starting at 3 mo of age (Fig 2.5B; Table 4). Lv Mass 
was significantly higher in BACHD compared to WT with significant differences starting at 9 
mo (Fig 2.5A). Functional measurements (Lv EF) were depressed in BACHD mice compared to 
WTs starting at 3 mo of age, and remained lower at all ages (Fig 2.5C). Throughout adult life, 
the hearts of BACHD mice were larger and functionally depressed compared to WTs. 
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Cardiac Fibrosis observed in both the Q175 and BACHD lines.   
We observed a significant reduction in both the body (−25%) and heart (−18%) weight in the 
Hom Q175 as compared to WT (Table 5). Therefore, at the end of the echocardiogram 
measurements, histological analysis of the hearts was performed to further characterize these 
abnormalities. The total area of coronal heart sections at the mid-ventricular level in the Hom 
Q175 was 33% and 23% smaller than that of WT and Het Q175, respectively (Table 5, Fig 
2.6A). In agreement with the echocardiogram data, the Lv lumen cross sectional area (CSA) 
(54%) and circumference (23%) were greatly reduced in the Hom Q175 (Table 5). No 
differences were found in the thickness of the Lv wall or the interventricular septum. The 
dimensions of the Het Q175 hearts were not significantly different from WT (Table 5). Next, we 
measured the CSA of individual cardiomyocytes stained with WGA (Fig 2.6B). While the WT 
cardiomyocytes exhibited a medium CSA of 204 ± 11 µm2, the CSA was 151 ± 4 µm2 and 
95 ± 8 µm2 in the Het and Hom Q175, respectively (ANOVA on ranks, H = 15.15, P < 0.0001). 
This dramatic reduction in size (53%) of the CSA of the cardiomyocyte in the Hom hearts was 
accompanied by an apparent disorganized cytoarchitecture of the myocardium (Fig 2.6B). 
Finally, histopathological analysis of the heart with Masson's trichrome stain revealed local 
pockets of fibrosis where the cardiomyocytes appeared to be replaced by scar tissue (Fig 2.6C). 
These areas, an indication of small necrotic lesions or infarcts, were present in the heart of all 
three genotypes with an average of 9.6 infarcts/section in the Hom Q175 vs 2–3 infarcts/section 
in the WT and Het Q175 (Fig 2.6D). Small fibrotic areas were occasionally seen in all the WT 
mice examined, frequently on the edge of the papillary formations in the Lv (Fig 2.6C). In the 
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mutants, the fibrotic pockets were seen in the ventricular wall of both the left and right 
ventricles, some of which were extensive. Interestingly, in the Hom Q175, these lesions were 
most commonly seen in the anterior part of the interventricular septum near the anterior groove, 
suggesting disruption of the blood supply to the heart (Fig 2.6C and D).  
 
To further assess the cardiac structure of WT and BACHD hearts, we sacrificed the mice at 
about 15 mo of age and processed their hearts Masson’s Trichrome to visualize fibrotic tissue or 
H&E staining. We did not detect any fibrotic staining in the WT hearts, while positive staining 
was present in 6 of the 9 BACHD mice (Fig 2.7A). Optical density measurements of fibrotic 
staining were significantly higher in BACHD mice compared to WTs (Fig 2.7B; Table 6). 
BACHD hearts displayed enlarged Lv (Fig 2.7C). Although these values did not reach 
significance, an increase in Lv diameter (19%) and septal thickness (20%) were observed in 
BACHD compared to WT, whilst no difference in right ventricle dimensions were found 
between genotypes (data not shown). Furthermore, no changes were found in the cross-sectional 
area of the BACHD cardiomyocytes (103 ± 15 µm2; n = 4) as compared to WT (121 ± 13 µm2, n 
= 4). 
 
Discussion: 
In this study, we sought to test the dual hypotheses that cardiovascular dysautonomia can be 
detected early in disease progression in the Q175 model and that this dysfunction varies with the 
daily cycle. We found overwhelming evidence for autonomic dysfunction including blunted 
daily rhythms in HR, reduced HRV, and almost a complete failure of the sympathetic arm of the 
  
40  
ANS during the baroreceptor challenge. Importantly, several aspects of the Q175 phenotype 
were found to vary with a diurnal and circadian phase dependence. For example, HRV deficits 
were more prominent during the day but it would have been difficult to detect during the night. 
Hence, the time of measurement and the circadian cycle has to be considered as a critical factor 
in the expression of HD symptoms. The Q175 mouse model of HD exhibits cardiovascular 
symptoms comparable to those seen in HD patients with a prominent sympathetic dysfunction 
during the resting phase. 
 
Q175 (Hom, Het) mice showed deficits in both diurnal and circadian activity rhythms in HR 
(Fig. 2.1) with the deficits in HR occurring in young adults while the deficits in CBT were not 
observed until middle age. The circadian rhythms in HR are independent of locomotor activity 
but dependent on an intact SCN [107–112]. The SCN projects to the dorsal subparaventricular 
zone [113,114], which is necessary for driving circadian rhythms of body temperature [115]. 
Young Hom Q175 exhibited highly pronounced tachycardia during their normal sleep time, with 
high HR and a reduced amplitude in the HR rhythm (Fig. 2.1). In addition, the normal strong 
correlation between activity and HR, which is mediated by the ANS, was dramatically reduced in 
the mutants (Fig. 2.2). These changes suggest that ANS disruption occurs early in disease 
progression in the Q175 line. In agreement, we also saw evidence in the BACHD of the circadian 
system failing to lower blood pressure during sleep [29]. Similarly, R6/1 mice have a higher HR 
than WT littermates in young but not older mutant mice [41]. However, in two other models 
(R6/2 and HdhQ150 lines), the HR was significantly reduced in symptomatic mice [46].  
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HRV is a measure of variation in the beat-to-beat (R-R) interval that reflects the dynamic balance 
of sympathetic and parasympathetic control of heart function. In WT mice, HRV displayed a 
robust diurnal and circadian rhythm consistent with circadian regulation of the ANS (Fig. 2.3). 
Both the LF and HF domains of the HRV exhibited robust daily rhythms. In the Q175 line, the 
HRV was low in young mutants (Hom, Het) and this reduction was largest during the rest phase 
(Fig. 2.3A). The power in the LF domain was significantly reduced in the young mutants with 
the biggest effects during the night (Fig. 2.3B). Traditionally, the LF is viewed as a measure of 
regulation by the sympathetic branch of the ANS, although it is more likely a general index of 
ANS function [39,40]. Thus, our data clearly indicate that the autonomic outflow is disrupted in 
the HD mutants. Autonomic dysfunction is likely responsible for the low HRV as well as the 
elevated HR during the rest phase (daytime) in Q175 mice. A similar reduction in HRV was 
previously observed in the BACHD line [10], and evidence of disrupted ANS leading to an 
unstable heart beat as well as elevated levels of the sympathetic transmitter (norepinephrine) 
were reported in the R6/1 model [41]. It is also possible that postsynaptic receptors are altered, as 
suggested by a recent study showing that acetylcholine receptors (measured by α-bungarotoxin 
binding) are reduced in the diaphragm of BACHD mice [116]. However, earlier work examined 
cardiac β1-adrenergic receptor densities in R6/2 and WT mice but did not see any genotypic 
differences [11]. In HD patients, a similar decrease in HRV has also been reported during the 
presymptomatic and early stages of HD progression [18,19,21]. Reduced HRV is generally 
considered an indication of poor cardiovascular health and a predictor for cardiovascular disease 
and mortality [35,117,118]. 
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The baroreceptor reflex is also a process dependent on autonomic function. Similar to the 
BACHD line [29], Q175 mice showed a dramatically blunted response in HR to the transient 
hypotension induced by NP suggesting that the sympathetic branch has impaired homeostatic 
reserve (Fig. 2.4). The primary deficit in the baroreceptor reflex in Q175 mice is unknown, as 
this process is mediated by various regions of the brain including the brainstem and 
hypothalamus, along with outputs from the ANS [18,119,120]. In HD patients, the detection of 
alterations in the baroreceptor circuit, such as the vagal nuclei and cerebral cortex, have 
established a possible structural cause for this dysfunction [19–21,119,120]. Ideally, 
identification of the site of dysfunction could be used to devise an appropriate therapeutic 
approach to manage symptoms in HD patients. Prior studies reported HRV deficits during the 
Valsalva maneuver, hand-grip test, and the head up tilt test in HD patients [20,22,42,43]. 
Furthermore, patients complain of dizziness and light-headedness upon standing, suggesting they 
suffer from orthostatic hypotension due to autonomic dysregulation and a deficient baroreceptor 
reflex [18,30]. The sympathetic nervous system appears to be most impacted during the very 
early stages of HD [18–20]. As the disease advances, the parasympathetic activity progressively 
decreases as well [20–22].  
 
The Q175 mice displayed an age-dependent progression in heart dysfunction beginning at 
presymptomatic stages (3 months). Both the structure and function of the heart exhibited 
significant alterations due to both age and genotype (Fig 2.5D and E). The mutants’ hearts were 
smaller and less functional by 6 months of age (Table 3 and 5) and worsen with age. Histological 
analysis of the hearts also found that the mutant hearts showed localized fibrotic lesions that 
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resembled those caused by myocardial infarction (Fig 2.6C and D) and imply that prior 
obstruction of the blood supply to the heart caused local cell death. These fibrotic infarcted areas 
are the histological signature of heart attacks.  Evidence for fibrosis has also been found in 
another HD model, the R6/2 line [16]. 
 
The echocardiographic measurements performed on BACHD mice showed changes in heart 
structure and function at an early age (Fig 2.5A-C). At this time point (3 mo), motor deficits 
[121] and circadian rhythm dysfunction [10] are just beginning thus the cardiovascular deficits 
are occurring very early in the disease progression in this model. Though the slope of the 
changes were similar between aging WT and BACHD animals, the ejection fraction (EF) ratio of 
15 mo old BACHD mice were close to or below 55, which is the threshold between normal heart 
function and failure. We suspect that the function would continue to weaken with age, which 
poses a challenge for the cardiovascular system, leaving BACHD mice more susceptible to 
serious cardiac events. The presence of cardiac fibrosis in 15 mo old BACHD mice (Fig 2.7) also 
provides evidence for cardiac stress that feeds forward to further impair heart function. WT mice 
show minimal fibrotic lesions at this age. The focal fibrotic lesions in the BACHD would be 
expected to alter wall motion synchrony and could explain the reduced EF.  
 
The presence of fibrosis that we observed in both the Q175 and BACHD models could also 
increase the likelihood of arrhythmias [122] although we did not observe any in our recordings. 
Though the incidence of arrhythmias has not yet been examined in HD patients, other lines of 
evidence suggest increased susceptibility including altered ANS input to the heart [20,123]. ANS 
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dysfunction is consistent among a number of HD animal models including the R6/1 [41] and the 
R6/2 models [46]. In the BACHD model, we have found significant alterations in the 
baroreceptor reflex and a decline in heart-rate variability that indicate dysfunctional ANS 
outflow [29]. With this work, we have provided evidence that the Q175 and BACHD line 
recapitulates cardiovascular dysfunction seen in HD patients as well as established an age-
dependent progression by which we can judge the impact of therapeutic interventions. 
 
Cardiovascular complications are a leading cause of death in HD patients [6,7,96,97]. To date, 
several of the HD mouse models have been shown to exhibit cardiovascular dysfunction [9–
12,17,29,41,46]. Mutant Htt is expressed in both the heart and brain [124], thus a critical 
question is whether the cardiovascular pathologies seen in HD are due to a deficit at the level of 
the cardiomyocytes or whether they are secondary to central nervous system dysfunction. For 
example, overexpression of an expanded polyQ track or mHtt in cardiomyocytes resulted in heart 
failure and a significantly reduced lifespan in both mice [17] and flies [16]. So at least some of 
our findings may be due to cardiomyocyte-specific deficits, e.g., the changes in the ECG 
waveform in young mutant mice. In addition, in HD patients, there is evidence of degeneration 
of brainstem nuclei, including those that control the regulation of heart function 
[19,20,42,67,125,126]. So it is likely that there is an HD-specific cardiomyopathology as well as 
cardiovascular pathology secondary to the HD-driven damage to the ANS. Overall, this body of 
preclinical data suggests that monitoring of the cardiovascular system in HD patients should start 
at an early age so therapeutic interventions can by employed to slow the progression of these 
pathological processes and prevent early death. Most importantly, our data suggest that this early 
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screening must include observations during the usual sleep hours of the day, as early anomalies 
may go undetected at the times of day that patients would usually interact with clinicians.  
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Chapter 3: Rescue of the cardiovascular symptoms in the BACHD mouse model 
 
Introduction: 
 
Mouse model of HD recapitulate aspects of the human disease including cardiovascular 
dysfunctions such as reduced contractility and cardiac output [10,29,41,46]. The animal model 
used in this chapter is the BACHD mouse line of mice, engineered to express the human 
mutation in the Htt gene, in a way that it can be excised by Cre recombinase (Cre) in a tissue 
specific manner [121]. Our previous study showed structural and functional changes in the 
BACHD mice as early as 3 months of age, which resemble aspects of the human HD [13,21,29]. 
Also, there is evidence that when soluble preamyloid oligomers similar to HD mutations are 
expressed exclusively in cardiomyocytes, the mice die from cardiac failure, suggesting that CV 
dysfunction is not solely secondary to neurodegeneration [16,17]. Therefore, we crossed the 
BACHD mouse line with a Myh6-Cre to reduce mHtt in the cardiomyocytes to obtain a better 
understanding of the role of cardiomyocytes in driving the CV symptoms in HD. Using this 
conditional BACHD mouse model, we assessed the cardiac function and structure with 
echocardiograms in the early disease progression. We also analyzed the gene expression of 
cardiac hypertrophic markers. Finally, we examined the impact of the reduction of mHtt in 
several behaviors that are known to be impacted by the HD mutation. Taken together, our study 
provides important insights into cardiovascular pathophysiology in HD.   
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Methods: 
 
Generation of BMYO mice  
BACHD mice on the C57BL6/J background along with littermate wild-type (WT) controls were 
acquired from the mouse mutant resource at The Jackson Laboratory, (JAX, Bar Harbor, Maine) 
in a colony maintained by the CHDI Foundation. αMHCCre (Myh6-Cre) were obtained from The 
Jackson Laboratory. BACHD and Myh6-Cre mice on the C57BL/6 background were bred to 
generate double transgenic, BACHD;Myh6-Cre (BMYO), with the mHtt floxed out in the 
cardiomyocytes (Fig 3.1). The following three genotypes were used in this study: WT, BACHD, 
and BMYO. Genotypes were confirmed by PCR of tail snips.    
 
WT (n = 8), BACHD (n = 8), and BMYO (n = 8) male mice were group housed and kept in a 
12:12 light/dark (LD) cycle with rodent chow provided ad libitum. Mice were examined with 
echocardiograms at 3 and 6 mo of age. After the last echocardiogram measurement, the heart and 
brain tissues of the mice were collected and morphologic and histological measurements were 
taken. All procedures followed guidelines of the National Institutes of Health and were approved 
by the UCLA Animal Research Committee.  
 
RNA Extraction 
WT, BACHD and BMYO mice (n = 3 per group) were used for gene expression analysis. Total 
RNA from the hearts were extracted using Trizol RNA isolation protocol (LifeTechnologies, 
Carlsbad, CA), then DNAse treated (TURBO DNA-free kit, Life Technologies) and column 
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purified (Pureline RNA Mini-kit, Life Technologies). RNA was used for Quantitative Real-Time 
PCR experiments described below. 
 
Quantitative Real-Time PCR 
One µg of total RNA was reverse transcribed using iScriptTM Reserve Transcription Supermix 
for RT-qPCR (Bio-Rad Laboratories). Quantitative real-time PCR (RT-qPCR) was performed 
using SYBR Green Mix (Applied Biosystems) on a CFX connect Real-Time System (Bio-Rad 
Laboratories). The gene expression was calculated using the 2-ΔΔCt method.  
 
To detect the human mHtt expression, primers for RT-qPCR were designed using the established 
protocol by Gray et al [121]. The forward primer recognized both endogenous mouse HD gene 
homolog and exogenous mhtt. Two reverse primers were designed to be species-specific. 
Forward: 5’-ATC TTG AGC CAC AGC TCC AGC CA-3’; reverse (human) 5’-GGC CTC CGA 
GGC TTC ATC AGG-3’; reverse (murine), 5’- TCT GAA AAC ATC TGA GAC TTC ACC 
AGA-3’. The primers used in this study also include the following: Myh6, Myh7, BNP, GATA4, 
Col1a, and Fibronectin (Qiagen).    
 
Western blotting 
Protein lysates from the heart and brain tissues were western blots were performed as previously 
described [13]. Immunoblots were probed with the anti-polyglutamine-expansion disease 
marker, 1C2 (1:1000, Chemicon), GAPDH (1:3000, GeneTex), and Fibronectin (1:500, Abcam) 
prepared in 5% blocking solution. To quantify, the protein levels were normalized to GAPDH.    
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Echocardiogram 
WT, BACHD, and BMYO mice (n = 8 per genotype) were group housed and kept in a 12:12 
light/dark (LD) cycle with rodent chow provided ad libitum. Mice were examined with 
echocardiograms at 3 and 6 mo of age. After the last echocardiogram measure, the heart and 
brain tissues of the mice were collected and morphologic and histological measurements were 
taken.  
 
Echocardiograms were measured using a Siemens Acuson Sequoia C256 instrument equipped 
with a 15L8 15MHz probe (Siemens Medical Solutions, Mountain View, CA) as previously 
described. Briefly, two-dimensional, M-mode echocardiography and spectral Doppler images 
enabled measurement of heart dimension and function (Left Ventricle (Lv) Mass), end-diastolic 
dimension (EDD), end-systolic dimension (ESD), posterior wall thickness (PWT), ventricular 
septal thickness (VST), Lv Ejection Fraction (Lv EF). The mice were sedated with 1% isoflurane 
vaporized in oxygen (Summit Anesthesia Solutions, Bend, OR) and HR was monitored using 
electrocardiogram to maintain physiological levels (between 450 and 650). 
 
Trichrome Histology  
Heart samples were harvested, perfused, and incubated in 4% paraformaldehyde at 4° C over 
night, followed by incubation in 30% sucrose in PBS at 4° C. The hearts were removed from the 
sucrose solution and embedded in Tissue Tek O.C.T. (Sakura Finetek). Frozen whole-heart 
blocks were sectioned at 8-10 µm thickness with a cryostat (Leica), mounted on Superfrost slides 
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(Fisherbrand), and stained with Masson’s Trichrome kit (Sigma-Aldrich). Masson’s Trichrome-
stained heart with the aid of Image J software.   
 
Behavioral studies 
Locomotor activity was recorded from single-caged mice with infrared motion sensors using our 
established protocols [127]. Locomotor activity was recorded in 3-min bins, and 10 days of data 
were averaged for analysis. The 10 days of activity data collected just before the motor 
performance tests was used. Analyzing the data, the period and rhythmic strength was 
determined as previously described [10,26,127]. The periodogram analysis used a χ2 test with a 
threshold of 0.001 significance, from which the amplitude of the periodicities was determined at 
the circadian harmonic to obtain the rhythm power. The amount of cage activity over a 24-h 
period was averaged over 10 days and reported here as the hourly arbitrary units (au/h). The 
number of activity bouts and the average length of bouts were determined using Clocklab 
(Actimetrics), where each bout was counted when activity bouts were separated by a gap of 21 
min (maximum gap: 21 min; threshold: 3 counts/min).  
 
The grip strength test was used to measure neuromuscular function as maximal muscle strength 
of forelimbs. The grip strength ergometer (Santa Cruz Biotechnology, Santa Cruz, CA) was set 
up on a flat surface with a mouse grid firmly secured in place. Peak mode was utilized to enable 
measurement of the maximal strength exerted. Mice were tested in their active phase under dim 
red light (3 lux), and prior to testing, mice were acclimated to the testing room.  Mice underwent 
five trials with an inter-trial interval of at least two minutes.  For each trial, a mouse was lowered 
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slowly over the grid, and only its forepaws were allowed to grip the grid. While the mouse was 
steadily pulled back, the experimenter ensured the mouse remained horizontal until the mouse 
was no longer able to grip the grid. The maximal grip strength value of the mouse was recorded 
each trial.  The grid was cleaned with 70% ethanol and allowed to dry before testing each mouse 
cohort.  The maximum value obtained per animal is reported as maximal strength divided by 
bodyweight. 
 
The challenging beam test was used to characterize the motor deficits of BACHD mutant mice in 
previous studies [10,127]. The beam narrows in 4 intervals from 33 mm > 24 mm > 18 mm > 6 
mm, with each segment spanning 253 mm in length. The home cage of each mouse is put on the 
end of the beam as the motivating factor. In this study, animals were trained on the beam for 5 
consecutive trials for two consecutive days. During each trial, each mouse was placed on the 
widest end of the beam and allowed to cross with minimal handling by the experimenter. On 
the testing day, a metal grid (10 Å~ 10 mm spacing, formed using 19-gauge wire) was overlaid 
on the beam. This overlaid grid increased the difficulty of the beam traversal task and provided a 
visual reference for foot slips made while crossing the grid. Each mouse was subjected to 5 
consecutive trials conducted during their active (dark) phase. Trials were recorded by a 
camcorder under dim red-light conditions (2 lux), supplemented with infrared lighting for video 
recording. The videos were scored post hoc by 2 independent observers for the number of 
missteps (errors) made by each mouse. The observers were masked as to the treatment group of 
the mice that they were scoring. An error was scored when any foot dipped below the grid. The 
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number of errors was averaged across the 5 trials per mouse to give the final reported values. The 
apparatus was cleaned with 70% alcohol and allowed to dry completely between trials. 
 
Results: 
 
Genetic reduction of mHTT in the cardiomyocyte 
To determine whether genetically reducing mHtt expression from the cardiomyocytes can rescue 
cardiovascular phenotypes observed in the BACHD mice, we crossed BACHD mice with Myh6-
Cre mice and generated three genotypes including WT, BACHD, BACHD;Myh6-Cre (BMYO) 
(Fig 3.1). We used these mice to confirm the reduction of mHtt mRNA and protein levels in the 
cardiomyocytes (Fig 3.2). In the heart, there were significant differences in the mRNA 
expression (one way ANOVA: F(2) = 125.5. P<0.001) with the levels of human mHtt 
significantly reduced in the BMYO hearts compared to the BACHD (Tukey: q = 18.584, P < 
0.001) (Fig 3.2).  In the striatum, there were overall significant differences in expression (one 
way ANOVA, F(2) = 87.706, P < 0.001), but there were no differences between the expression in 
BACHD and BMYO groups (Tukey: q = 0.853, P = 0.824) (Fig 3.2).  There were no differences 
between the three groups in expression of endogenous mouse Htt in the heart (F(2) = 2.045, P = 
0.210) or striatum (F(2) = 0.852, P = 0.473).   
 
We used western blots to measure polyglutamine-expansion in the heart and striatum of the three 
genotypes (Fig 3.2).  In the heart, there were significant differences in the 1C2 protein (one way 
ANOVA: F(2) =162.549, P <0.001) with the levels of the expansion significantly reduced in the 
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BMYO hearts compared to the BACHD (Tukey: q = 20.801, P <0.001).   In the striatum, there 
were overall significant differences in 1C2 expression (one way ANOVA: F(2) = 27.098, P < 
0.001), but there were no differences between the expression in BACHD and BMYO groups 
(Tukey: q = 2.197, P = 0.334). 
 
In summary, we found a significant reduction (92%) in the mHtt expression in the BMYO hearts 
compared with the BACHD hearts, but not in the striatum. Consistent with the mRNA results, 
BMYO mice had about 89% reduction of the polyglutamine expansion marker 1C2 in the hearts 
compared with the BACHD mice.            
 
The genetic reduction of the mHtt expression improves some cardiovascular functions in BMYO 
mice.  
To assess changes in the cardiac structure and function of the three lines of mice, we utilized 
echocardiograms at 3 and 6-month age. Consistent with our earlier data (Chapter 2), at 3 months 
of age, there were few significant differences between the 3 genotypes (Table 7).  At this age, the 
Lv of the mutants exhibited an increased mass (not significantly) and the BACHD exhibited a 
reduced ejection fraction (P = 0.035) compared to the other groups.  At 6 mo of age (Fig 3.3; 
Table 7), both the BACHD and the BMYO exhibited enlarged left ventricle.  This feature of the 
BACHD was not altered by the loss of the mHtt. On the other hand, the ejection fraction and 
heart rate was reduced compared to WT in the BACHD but not in the BMYO.  For both of these 
parameters, the measurements from the BMYO looked more like WT.  While the heart’s 
contractility measurements (Lv fractional shortening) did not differ among all three genotypes 
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(Fig 3.3), there was a clear trend for a reduction in the BACHD compared to the other groups.  
Overall, at the age points examined, most of the echocardiogram parameters did not vary 
significantly.  The EF refers to the percentage of blood that is pumped out of a filled ventricle 
with each heartbeat and this measure appeared to be most sensitive to the levels of mHtt in the 
cardiomyocytes.   
 
The reduction of mHtt impacted gene expression within the BMYO hearts. 
We examined the mRNA expression of disease markers in the hearts at 6-month of age using 
RT-qPCR (Fig 3.4; Table 8). We found that collagen 1a (Col1a) mRNA expression was 
significantly higher level in the BACHD hearts compared to WT although there was no 
significant difference between WT and BMYO.   
 
Next, we looked at the expression of several genes important in cardiomyocyte development 
including Myh6, Myh7 and GATA4. These genes are known to be up-regulated in response to 
injury or cardiomyocyte remodeling [128–130]. We found significant increases in the expression 
of Myh6 and GATA4 in the hearts of the BACHD and found that this up-regulation was not seen 
in the BMYO line. Finally, we looked at expression of brain natriuretic peptide (BNP), which is 
a hormone secreted by cardiomyocytes in the heart ventricles in response to stretching. Again we 
found that the BACHD mutants exhibited higher expression while the BMYO line showed much 
lower expression. Together this data indicates that, at least transcriptionally, the BACHD hearts 
were under stress and that these changes were reversed in the BMYO line.    
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The reduction of mHtt may have reduced fibrosis within the BMYO hearts. 
To assess the cardiac structure of the hearts, we sacrificed the mice at about 6 mo of age and 
processed their hearts and used Masson’s Trichrome to visualize fibrotic tissue (Fig 3.5). We did 
not detect any fibrotic staining in the WT hearts, while both BACHD and BMYO hearts showed 
small fibrosis on the edges of the hearts. These fibrotic regions remain to be quantified.  
Similarly, western blots were used to measure the protein levels of fibronectin. The 
concentration of the anti-sera still needs to be quantified.        
 
The reduction of mHtt in the heart improved some aspects of motor behavior.   
There is compelling evidence that physical activity is an sensitive biomarker for chronic 
cardiovascular disease [131,132]. Therefore, in our final experiment, we sought to determine 
whether the genetic reduction of mHtt expression in the cardiomyocytes had beneficial impact on 
motor function in the BACHD mice using two measures: overall physical activity and grip 
strength (Fig 3.6; Table 9). We found that both BACHD and BMYO exhibited a significant 
reduction in activity over 24 hr compared to WT but that the BMYO line exhibit more activity 
than BACHD.  The strength of the daily rhythms as measured by power of the periodograms was 
similar in both of the mutant lines so the rhythmicity of the activity data was not impacted by the 
reduction in mHtt in the heart.  Grip strength was improved in the BMYO line compared to 
BACHD alone.  Finally, performance on the challenge beam as measured by errors made was 
actually highest in the BMYO line.   
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Overall, the two parameters that have been suggested as biomarkers of cardiovascular function 
(total activity, grip strength) were improved by the reduction of mHtt in the heart. 
      
 
Discussion:  
As described in Chapter 1, both the clinical and preclinical research indicate that cardiovascular 
dysfunction should be considered a core symptom of at least a subset of HD patients. There is 
some evidence for cardiomyopathy, but these is even stronger evidence for dysautonomia 
(dysfunctional autonomic nervous system, ANS) in HD patients that can be detected early in the 
disease progression. Mutant huntingtin (mHTT) is ubiquitously expressed so the cardiomyopathy 
could be the result of deficits in the cardiomyocytes themselves and/or in the dysautonomia 
driven by the nervous system.  In this study, we utilized the BACHD mouse model that allows 
specific reduction of the mHtt expression in the cardiomyocytes when crossed with the Myh6-
Cre mouse line. Our data confirmed successful reduction in the mHTT mRNA and protein levels 
of the BMYO hearts by close to 90% (Fig 3.2). The Cre-driven recombination would have 
occurred early in development so that the BMYO mice that we evaluated would have had greatly 
reduced mHtt from the heart with high levels of mHtt in the brain. This genetic construct gives 
us a unique model to evaluate the contribution of the mHtt in the cardiomyocytes to the 
cardiovascular disease associated with HD.   
One limitation of our approach is the possibility that toxicity of the prolonged Cre expression to 
the hearts. It has been suggested that prolonged Cre expression driven by the α-myosin heavy 
chain promoter can be cardiotoxic [133,134]. Unlike the BACHD mice that can live up to 18 
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months [10,135], we observed that most of BMYO mice did not survive longer than a year which 
may be due to cardiotoxicity (data not shown).  
 
 
We examined the cardiovascular function and structure using echocardiograms in all three 
genotypes at 6-month of age. Most of the functional echo parameters did not vary between the 
genotypes (Table 7).  There were two notable exceptions.  As previously observed (Chapter 2), 
the Lv mass of the BACHD hearts was larger than WT.  The divergence between the genotypes 
was already seen at 3 months but was not significant until 6 months of age.  This hypertrophy 
was also observed in the BMYO hearts suggesting that the driver was not the mHtt in the 
cardiomyocytes.  In addition, Lv ejection fraction (EF) was reduced in the BACHD while the EF 
of the BMYO heart was comparable to comparable to the WT levels (Fig 3.3).  The EF refers to 
the percentage of blood that is pumped out of a filled ventricle with each heartbeat. It is the 
relation between the amount of blood expelled during each cardiac cycle relative to the size of 
the ventricle. It is important to note that a Lv EF of 65 – 75% is considered normal under 
physiologic loading conditions for mice, with an EF of below 65% being considered reduced.  So 
even the BACHD hearts were still working at functional levels at the 6 mo time point.  The 
findings with Lv EF were closest to our predictions for a cardiomyopathy driven by mHtt in the 
heart.  The FS % exhibited a similar trend but the differences were not significant.  Perhaps we 
needed to wait to an older age to see more robust differences with the echocardiogram.  Prior 
work indicated that the EF of the BACHD hearts steadily declined with age after the 6 mo time 
point (Chapter 2) so we are looking at the peak of cardiac output. Taken together, these 
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functional data suggest that reduced mHtt expression in the cardiomyocytes help improve Lv EF 
in the BMYO mice.    
 
In prior work examining the hearts of middle-aged BACHD mice (>12 mo), we found striking 
fibrosis as measured by trichrome staining (Chapter 2).  In the present study, we visually 
observed some fibrotic regions in the BACHD and BMYO mouse hearts, but not in the WT (Fig 
3.5). We were unable to quantify the possible differences in staining before the COVID19 
research stoppage.  Interestingly, the Col1a mRNA expression level in the BMYO hearts was 
significantly reduced compared to BACHD (Fig 3.4). Therefore, we expect to similar differences 
in fibrosis as measured by trichrome staining.  An increase in fibrosis in the heart could explain 
the reduction in the ejection fraction found in the echo data.  Histological studies have suggested 
that myocardial fibrosis can be an important driver of a reduction in EF [136,137]. We also 
looked at the expression of several genes important in ventricular remodeling including Myh6, 
Myh7 and GATA4. These genes are known to be up-regulated in response to injury or 
cardiomyocyte remodeling [128–130]. We found significant increases in the expression of Myh6 
and GATA4 in the hearts of the BACHD and found that this up-regulation was not seen in the 
BMYO line. We examined expression of brain natriuretic peptide (BNP), which is a hormone 
secreted by cardiomyocytes in the heart ventricles in response to stretching [138,139]. Again we 
found that the BACHD mutants exhibited higher expression while the BMYO line showed much 
lower expression. Together this data indicates that, at least transcriptionally, the BACHD hearts 
were under stress and that these changes were reduced in the BMYO line.    
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Finally, we looked at impact of the cross on behavioral markers of cardiovascular health.  In 
humans, there is strong evidence that grip strength provides a biomarker for cardiovascular 
function [131,132,140]. For example, a recent study from the Sattar’s group examined the 
associations of objectively measured grip strength (GS) with incident heart failure (HF) [141].  
Using the UK Biobank dataset, the authors evaluated data from 374,493 individuals. During 4 
years, 631 HF events occurred in those with GS data. Higher CRF was associated with 18% 
lower risk for HF (hazard ratio [HR], 0.82; 95% CI, 0.76-0.88) per 1-metabolic equivalent 
increment increase and higher GS was associated with 19% lower incidence of HF risk (HR, 
0.81; 95% CI, 0.77-0.86) per 5-kg increment increase. When GS was standardized, the HR for 
GS was 0.65 per 1-SD increment (95% CI, 0.58-0.72).  While this data is correlational, the 
literature indicates that objective measurements of physical function (GS) are strongly associated 
with lower HF incidence. In this study, we found that grip strength was reduced in the BACHD 
compared to WT and that this measure was improved by the excision of the mHtt. Overall, 
physical activity in this case measured by total activity over 24 hr followed the same trend. Both 
the mutant groups exhibited the reduction in the strength of the rhythm as measured by power 
(Fig 3.6).  Most other rhythmic parameters were not improved by the reduction of the mHtt from 
the heart.  The central circadian clock is based in the hypothalamus so improvements in circadian 
output were not expected from this cross.     
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 In summary, the clinical and preclinical research indicate that cardiovascular dysfunction should 
be considered a core symptom of at least a subset of HD patients. There is strong evidence for 
dysautonomia that can be detected early in the HD progression.  There is also some evidence for 
cardiomyopathy and our results suggest that there is cardiac specific pathology in the BACHD 
pre-clinical model.  Reducing mHtt specifically from cardiomyocytes did improve the Lv EF as 
measured by the echocardiogram, reduced the expression of several markers of heart disease, and 
improved a behavioral marker of cardiovascular health. We believe that this data argues that 
cardiomyopathy should be considered as part of the consequences of the HD mutation.   
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Discussion: Clinical significance and future directions 
Cardiovascular (CV) disease is a leading cause of early death in the Huntington’s disease (HD) 
patient population. Animal models are needed to understand how the mutant Htt causes 
pathology in the CV system in order to development new treatment strategies.  In this thesis 
work, we first sought to determine if CV symptoms could be measured in the Q175 and BACHD 
mouse models of HD.  In this work, we sought to test the dual hypotheses that cardiovascular 
dysautonomia can be detected early in disease progression in the Q175 and BACHD models and 
that this dysfunction varies with the daily cycle. We found overwhelming evidence for 
autonomic dysfunction including blunted daily rhythms in HR, reduced HRV, and almost a 
complete failure of the sympathetic arm of the ANS during the baroreceptor challenge. 
These were first demonstrations that these mouse models exhibited CV symptoms like the HD 
patients.  Furthermore, they suggest that the disrupted circadian regulation could contribute to 
the pathology.   
 
Next, we we sought to reduce mHtt expression in cardiomyocytes to ameliorate CV symptoms 
seen in the BACHD mice. Using this genetic reduction, we could improve some aspects of heart 
function and motor deficits in these mice. However, reducing mHtt in the cardiomyocytes was 
not sufficient to provide striking impact on the functional and structural changes in the BACHD 
mouse hearts. Our findings indicate that cardiovascular focused treatments may extend the 
health-span of the patients but the autonomic dysfunction will also need to be considered.    
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In HD clinical trials, antisense oligonucleotides (ASO) have shown promise to decrease the 
mHtt. For example, the drug candidate, RG6042 by Roche, is currently in the phase 3 trial 
investigating the safety and efficacy of long-term use in the HD patients. Intrathecal 
administration of this ASO therapy was effective at decreasing the total amount of mHtt 
measured in the cerebrospinal fluid by 40-60% [142]. It is yet unknown how much of reduction 
is required to result in the positive effect on the disease progression. The efficient way to 
measure the clinical outcomes is still unclear but CV measures like HRV could provide 
inexpensive biomarkers for treatment efficacy. These clinical studies are heavily relying on the 
limited studies with the mouse models. Thus, many questions of study remain to be pursued in 
the future preclinical studies to develop the effective therapeutic interventions and validate the 
effectiveness of the approach.  
 
 
In investigating the impact of TRF on the gene expression rhythms in the BACHD mouse hearts 
(Appendix), Klf15 exhibited the largest changes among the genes of interest. Many studies have 
documented that Klf15 plays a key role in regulating oscillatory genes in the heart [80] and 
cardiac hypertrophy [143,144]. Our data show that feeding schedule induced the amplitudes of 
the Klf15 expression rhythms in BACHD hearts. Echocardiograms demonstrated that BACHD 
mice had larger left ventricular mass already at 3 mo compared with WT controls (See Chapter 
2). Interesting findings from studies in this work suggest that potential therapeutic strategies that 
aim to modulate the expression of Klf15 to boost circadian output as well as to prevent 
hypertrophy in the HD. Furthermore, the cardiovascular symptoms in HD patients should be 
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better understood in the future studies. Underlying mechanisms of many CV symptoms including 
autonomic dysfunction, and cardiac hypertrophy need to be delineated to further advance the 
therapeutic approaches to prevent mortality and to ultimately treat this devastating disease, HD. 
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Appendix: Impact of time-restricted feeding on the gene expression rhythms in the BACHD 
mouse hearts 
 
Introduction: 
 
HD patients in the early stages of the disease progression exhibit low HRV [18,19,21], which is a 
general indication of poor cardiovascular outcomes [35,117,118]. The decreased HRV was also 
observed in the BACHD mouse line [10]. In our recent study, we have shown that time-restricted 
feeding (TRF) improves activity, motor performance, and sleep rhythms in the BACHD [74]. 
Additionally, TRF had the most robust effect on HRV, suggesting enhanced autonomic function 
in the BACHD mice [74]. Using in vivo imaging of BACHD and WT PER2::LUC mice, we 
showed that TRF elevated the amplitude and shifted the phase of the rhythm in the heart but not 
in the SCN. These findings demonstrated that TRF ameliorates various symptoms and boosts the 
circadian rhythms in the BACHD mice. In this appendix, we investigated the impact of TRF on 
the gene expression rhythms in the BACHD mouse hearts by collecting tissue at six time points 
around the 24-hr cycle. We focused on a set of the target genes including core clock, circadian 
output, clock-driven transcription factors, and metabolic genes.  
 
 
Methods: 
 
Time-restricted feeding (TRF) 
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BACHD and WT mice were first entrained to a 12:12 h Light Dark (LD) cycle for at least 2 
weeks prior to any treatment. Experimental animals were then exposed to one of two feeding 
conditions: food available ad libitum (ad lib) or food available for 6 h during the middle of the 
active phase during zeitgeber time (ZT) 15-21. By definition, ZT 12 is the time when the lights 
are turned off when the mice are in an LD cycle. In this study, four groups were used with two 
genotypes, BACHD and WT, and two feeding conditions (ad lib or TRF). Single-housed mice 
were in a cage equipped with a custom-made programmable food hopper that could temporally 
control access to food (standard chow) and prevent food consumption during restricted times. 
Mice are coprophagic, and the mice were not moved to new cages between their daily feeding 
and fasting cycles. It is possible that the mice consumed their own feces during the fast interval. 
These cages were also equipped with an infrared (IR) motion detector to give us the ability to 
measure cage activity. The mice were held in these conditions for a total of 3 months (from 3 mo 
to 6 mo of age) [74].  
 
Time course tissue collection  
In order to measure the gene expression of the target genes around the clock, the heart tissues of 
the mice (n=4 per group) were quickly collected at ZT 2, 6, 10, 14, 18, and 22 after the last 
behavioral measurement. Thus, the total of 24 mice were used for each group, resulting in 96 
samples harvested.   
 
Quantitative Real-Time PCR 
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Total RNA was extracted from the heart tissues using our lab’s established protocol consistent 
with previous chapters. One µg of total RNA was reverse transcribed using iScriptTM Reserve 
Transcription Supermix for RT-qPCR (Bio-Rad Laboratories). Quantitative real-time PCR (RT-
qPCR) was performed using SYBR Green Mix (Applied Biosystems) on a CFX connect Real-
Time System (Bio-Rad Laboratories). The gene expression was calculated using the 2-ΔΔCt 
method. The expression of the target genes was normalized to GAPDH and the relative 
expression was analyzed. The primers used in this study are the following: Bmal1, Per2, Dbp, 
PPAR γ, SIRT1, Pdk4, Ucp3, Klf15, and GAPDH (Qiagen).    
 
Statistical Analysis 
We were interested in determining if TRF can alter the rhythms in gene expression measured 
from the heart of WT and BACHD mice.  Treated BACHD mice (TRF group) were compared to 
age-matched untreated BACHD mice (ad lib group) in all experiments. The sample size per 
group was determined by both our empirical experience with the variability in the prior measures 
in the BACHD mice and a power analysis (SigmaPlot, SYSTAT Software, San Jose, CA) that 
assumed a power of 0.8 and an alpha of 0.05.  To determine the impact of the treatment on 
temporal expression waveforms, we used a two-way analysis of variance (2-way ANOVA) with 
treatment and time as factors.  We also used a 2-way ANOVA to assess the impact of the 
treatment on the amplitude and phase of the rhythms.  Pairwise Multiple Comparison Procedures 
were made using the Holm-Sidak method. Statistical analysis was performed using SigmaPlot. 
Data were examined for normality (Shapiro-Wilk test) and equal variance (Brown-Forsythe test).  
Between-group differences were determined significant if p < 0.05. All values are reported as 
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group mean ± standard error of the mean (SEM). We report the t- or F-values as well as the 
degrees of freedom. Future analysis will utilize the JTK Clock software [145]. 
 
Results 
Please see Figure Appendix 1.  
PER2: In WT mice, we used a 2-way ANOVA to evaluate expression using time and genotype 
as factors.  We found significant effects of time (F5 = 72.252, P < 0.001) but not treatment (F1 = 
2.973, P = 0.093).  There was a significant interaction between time and treatment (F5 = 2.827, P 
= 0.03).  Using the Holm-Sidak multiple comparison procedure, there was a significant impact of 
treatment at ZT 14 (t = 3.543, P = 0.001).  
 
In the BACHD mice, we found significant effects of time (F5 = 47.037, P < 0.001) but not 
treatment (F1 = 0.733, P = 0.398).  There was a significant interaction between time and 
treatment (F5 = 3.246, P = 0.016).  Using the Holm-Sidak multiple comparison procedure, none 
of the phases showed a significant impact of treatment. 
 
Finally, using a 2-way ANOVA to evaluate the amplitude (peak/trough) of the rhythms using 
genotype and treatment, we did not find any significant effect.   
 
Therefore, our data indicate that all of the groups exhibited a robust rhythm in Per2 expression 
and TRF did significantly increase the expression of WT mice at ZT 14.   
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BMAL1:  In WT mice, we used a 2-way ANOVA to evaluate expression using time and 
genotype as factors.  We found significant effects of time (F5 = 76.719, P < 0.001) but not 
treatment (F1 = 1.231, P = 0.275).  There was not a significant interaction between time and 
treatment (F5 = 1.304, P = 0.284).  Using the Holm-Sidak multiple comparison procedure, there 
was a significant impact of treatment at ZT 2 (t = 2.599, P = 0.013).  
 
In the BACHD mice, we found significant effects of time (F5 = 35.830, P < 0.001) but not 
treatment (F1 = 3.540, P = 0.068).  There was a significant interaction between time and 
treatment (F5 = 3.398, P = 0.013).  Using the Holm-Sidak multiple comparison procedure, there 
was a significant impact of treatment at ZT 2 (t = 4.106, P < 0.001). 
 
Finally, using a 2-way ANOVA to evaluate the amplitude (peak/trough) of the rhythms using 
genotype and treatment as factors.  We did not find a significant impact of genotype (F1 = 0.380, 
P = 0.549) but there was a significant effect of treatment (F1 = 4.940, P = 0.046).     
 
Therefore, our data indicate that all of the groups exhibited a robust rhythm in Bmal1 expression 
and TRF did significantly increase the expression of WT and BACHD mice at ZT 2.  The TRF 
treatment significantly increased the amplitude of the rhythms.   
 
DBP: In WT mice, we used a 2-way ANOVA to evaluate expression using time and genotype as 
factors.  We found significant effects of time (F5 = 19.601, P < 0.001) but not treatment (F1 = 
0.210, P = 0.649).  There was not a significant interaction between time and treatment (F5 = 
  
69  
1.577, P = 0.191).  Using the Holm-Sidak multiple comparison procedure, there was a significant 
impact of treatment at ZT 6 (t = 2.529, P = 0.016).  
 
In the BACHD mice, we found significant effects of time (F5 = 29.027, P < 0.001) but not 
treatment (F1 = 2.022, P = 0.164).  There was a significant interaction between time and 
treatment (F5 = 3.743, P = 0.008).  Using the Holm-Sidak multiple comparison procedure, there 
was a significant impact of treatment at ZT 6 (t = 3.865, P < 0.001) and ZT 10 (t = 2.136, P < 
0.040). 
 
Finally, using a 2-way ANOVA to evaluate the amplitude (peak/trough) of the rhythms using 
genotype and treatment as factors.  We did not find a significant impact of genotype (F1 = 2.034, 
P = 0.179) but there was a significant effect of treatment (F1 = 12.107, P = 0.005).     
 
Therefore, our data indicate that all of the groups exhibited a robust rhythm in Dbp expression 
and TRF did significantly increase the amplitude of the rhythms of expression in WT at ZT 6 and 
BACHD at ZT 6 & 10.   
 
KLF15: In WT mice, we used a 2-way ANOVA to evaluate expression using time and genotype 
as factors.  We found significant effects of time (F5 = 6.068, P < 0.001) but not treatment (F1 = 
1.975, P = 0.164).  There was a significant interaction between time and treatment (F5 = 3.882, P 
= 0.006).  Using the Holm-Sidak multiple comparison procedure, there was a significant impact 
of treatment at ZT 14 (t = 2.558, P = 0.015) and ZT 18 (t = 3.493, P = 0.001). 
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In the BACHD mice, we found significant effects of time (F5 = 8.130, P < 0.001) but not 
treatment (F1 = 0.359, P = 0.553).  There was a significant interaction between time and 
treatment (F5 = 6.748, P < 0.001).  Using the Holm-Sidak multiple comparison procedure, there 
was a significant impact of treatment at ZT 10 (t = 2.383, P = 0.023) and ZT 14 (t = 4.741, P < 
0.001). 
 
Finally, using a 2-way ANOVA to evaluate the amplitude (peak/trough) of the rhythms using 
genotype and treatment as factors.  We found a significant impact of genotype (F1 = 5.210, P = 
0.041) and treatment (F1 = 28.126, P = 0.001).     
 
Therefore, our data indicate that all of the groups exhibited a robust rhythm in Klf15 expression 
and TRF did significantly increase the amplitude of the rhythms of expression in WT at ZT 14 & 
18 and BACHD at ZT 10 & 14.   
 
PPAR γ:  In WT mice, we used a 2-way ANOVA to evaluate expression using time and 
genotype as factors.  We did not find significant effects of time (F5 = 0.379, P = 0.860) or 
treatment (F1 = 0.669, P = 0.419).  There was not a significant interaction between time and 
treatment (F5 = 1.226, P = 0.317).  Using the Holm-Sidak multiple comparison procedure, there 
were no significant impact of treatment at any phase.   
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In the BACHD mice, we did not find significant effects of time (F5 = 1.378, P = 0.255) or 
treatment (F1 = 1.043, P = 0.314).  There was not a significant interaction between time and 
treatment (F5 = 1.675, P = 0.166).  Using the Holm-Sidak multiple comparison procedure, there 
were no significant impact of treatment at any phase.   
 
Finally, using a 2-way ANOVA to evaluate the amplitude (peak/trough) of the rhythms using 
genotype and treatment as factors.  We did not find a significant impact of genotype (F1 = 0.681, 
P = 0.425) and treatment (F1 = 2.842, P = 0.116).     
 
Therefore, our data indicate that none of the groups exhibited a robust rhythm in PPAR gamma 
expression and TRF did not alter the amplitude of the rhythms of expression. 
 
SIRT1: In WT mice, we used a 2-way ANOVA to evaluate expression using time and genotype 
as factors.  We did not find significant effects of time (F5 = 1.507, P = 0.212) or treatment (F1 = 
0.006, P = 0.937).  There was not a significant interaction between time and treatment (F5 = 
0.240, P = 0.942).  Using the Holm-Sidak multiple comparison procedure, there were no 
significant impact of treatment at any phase.   
 
In the BACHD mice, we found a significant effect of time (F5 = 3.546, P = 0.010) but not 
treatment (F1 = 0.017, P = 0.898).  There was not a significant interaction between time and 
treatment (F5 = 2.338, P = 0.062).  Using the Holm-Sidak multiple comparison procedure, there 
were no significant impact of treatment at any phase.   
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Finally, using a 2-way ANOVA to evaluate the amplitude (peak/trough) of the rhythms using 
genotype and treatment as factors.  We did not find a significant impact of genotype (F1 = 0.654, 
P = 0.434) or treatment (F1 = 2.962, P = 0.111).     
 
Therefore, our data indicate that only the BACHD exhibited a rhythm in Sirt1 expression and 
TRF was ineffective in altering the expression of this gene. 
 
UCP3: In WT mice, we used a 2-way ANOVA to evaluate expression using time and genotype 
as factors.  We found significant effects of time (F5 = 5.986, P < 0.001) but not treatment (F1 = 
2.561, P = 0.118).  There was not a significant interaction between time and treatment (F5 = 
1.234, P = 0.314).  Using the Holm-Sidak multiple comparison procedure, there was not a 
significant impact of treatment at any phase.   
 
In the BACHD mice, we found significant effects of time (F5 = 8.895, P < 0.001) but not 
treatment (F1 = 1.301, P = 0.262).  There was not a significant interaction between time and 
treatment (F5 = 2.238, P = 0.072).  Using the Holm-Sidak multiple comparison procedure, there 
was a significant impact of treatment at ZT 10 (t = 2.032, P = 0.050) and ZT 14 (t = 2.262, P < 
0.030). 
 
Finally, using a 2-way ANOVA to evaluate the amplitude (peak/trough) of the rhythms using 
genotype and treatment as factors.  We found no significant impact of genotype (F1 = 0.243, P = 
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0.631) but there was a significant impact of treatment on the amplitude of the rhythms (F1 = 
6.413, P = 0.026).     
 
Therefore, our data indicate that all of the groups exhibited a robust rhythm in UCP3 expression 
and TRF did not impact the amplitude of WT rhythms.  On the other hand, TRF did increase the 
amplitude of the rhythm of expression in the BACHD at ZT 10 & 14.   
 
PDK4: In WT mice, we used a 2-way ANOVA to evaluate expression using time and genotype 
as factors.  We found not significant effects of time (F5 = 2.362, P = 0.059) but there was an 
impact of treatment (F1 = 5.954, P = 0.020).  There was not a significant interaction between 
time and treatment (F5 = 2.234, P = 0.072). Using the Holm-Sidak multiple comparison 
procedure, there was a significant impact of treatment at ZT 14 (t = 3.566, P = 0.001). 
 
In the BACHD mice, we found significant effects of time (F5 = 8.130, P < 0.001) but not 
treatment (F1 = 0.359, P = 0.553).  There was a significant interaction between time and 
treatment (F5 = 6.748, P < 0.001).  Using the Holm-Sidak multiple comparison procedure, there 
was a significant impact of treatment at ZT 10 (t = 2.383, P = 0.023) and ZT 14 (t = 4.741, P < 
0.001). 
 
Finally, using a 2-way ANOVA to evaluate the amplitude (peak/trough) of the rhythms using 
genotype and treatment as factors.  We found a significant impact of genotype (F1 = 5.210, P = 
0.041) and treatment (F1 = 28.126, P = 0.001).     
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Therefore, our data indicate that all of the groups exhibited a robust rhythm in PDK4 expression 
and TRF did significantly increase the amplitude of the rhythms of expression in WT at ZT 14 & 
18 and BACHD at ZT 10 & 14.   
 
 
Summary 
 
Overall, time restricted feeding could alter gene expression rhythms in the heart of BACHD and 
WT mice.   
 
First we examined rhythms in the core clock genes, Bmal1 and Per2.  With this cohort of mice (6 
months of age), we did not see a significantly reduced Per2 expression rhythm as we had seen 
using PER2::LUC driven bioluminescence (Chapter 2). We cannot explain this difference but 
also noted that these mice are less impacted by the mutation (see Chapter 4) than the original 
cohorts.  All of the groups exhibited robust daily rhythms in the expression of Per2 and Bmal1.  
The TRF treated mice exhibited higher amplitude rhythms with peak expression at ZT 14 for 
Per2 and ZT 2 for Bmal1. Together this data shows that scheduled feeding can alter the 
amplitude the rhythm of the molecular circadian clockwork in the heart.     
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Next, we looked at the expression of two of the key molecular output genes: albumin D site-
binding protein (Dbp) and kruppel-like factor 15 (KLF15). The mechanisms by which the 
circadian clock regulates the transcription of other genes has been particularly well studied for 
the Dbp gene. BMAL1 and CLOCK bind to E boxes in the promoter region of Dbp to control 
transcription [146]. The circadian regulation of this gene has been particularly well studied in 
cell culture but not much is known about its expression in the heart. Here we show that both WT 
and BACHD hearts exhibit robust rhythms and that TRF increased the amplitude of the 
expression rhythms. Prior work has shown that KLF15 governs a biphasic transcriptomic 
oscillation in the heart with a maximum ATP production phase and a remodeling and repair 
phase corresponding to the active and resting phase of a rodent [80]. Depletion of KLF15 in 
cardiomyocytes leads to a disorganized oscillatory behavior without day/night partition despite 
an intact core clock. Thus, KLF15 is a nodal connection between the clock and rhythmicity in the 
heart.  In the heart, KLF15 in the heart plays a key role in controlling the transcription of cardiac 
metabolism during fasting [147] and plays a protective role in preventing hypertrophy [143].  
Based on this past data, it is perhaps not surprising that TRF regulates the phase and amplitude of 
the rhythm in KLF15 in the heart. Together this data shows that TRF treatment effectively 
regulates expression of key circadian output genes.   
 
 
As metabolism and mitochondrial function are known to be rhythmic in the heart, we examined 
the expression of a couple of genes linked to metabolism. Uncoupling protein 3 (UCP3) is a key 
protein involved in mitochondrial metabolism and function while pyruvate dehydrogenase 
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kinase-4 (PDK4) is critical for pyruvate oxidation. Both of these genes have been shown to be 
rhythmic in the heart in prior work [76] and we found robust rhythms in both genes. TRF 
increased the amplitude of gene expression in both of these genes.   
 
Our experiments did turn up some unanticipated finding. In the liver, both PPAR γ and SIRT1 
are rhythmic and are regulated by feeding schedules [148]. PPAR γ is known to regulate the 
BMAL1 gene expression and its deletion in the vasculature leads to decrease circadian variations 
in BP and HR [149]. Therefore, we were surprised to not be able to find a rhythm in expression 
in these gene nor did we see any evidence that TRF regulated the expression of these genes. We 
cannot explain these unexpected findings at this time.  
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Figure 1. 1  
Huntington’s disease (HD) is traditionally considered a motor disease treated by neurologists. 
However, there is increasing evidence that HD patients and animal models exhibit cardiovascular 
(CV) symptoms including dysautonomia (dysfunctional autonomic nervous system, ANS). 
Dysautonomia has been well-characterized in PD, and we believe that it is also a core symptom of 
a subset of HD patients and may be usefully applied to segregate this patient population for tailored 
treatments. There is also a growing body of evidence that HD patients and animal models exhibit 
disruption in circadian timing although not in sleep homeostasis. In our work, we have been testing 
the hypothesis that dysfunction in the circadian system in HD contributes to the CV disease and, 
in this review, we will summarize our progress. 
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Figure 1. 2 
Baroreceptor reflex is disrupted in mouse models of HD. In the baroreceptor reflex, changes in BP 
are detected by the baroreceptors and evoke compensatory changes in ANS. The Q175 and 
BACHD mutants showed a dramatically blunted response in HR to the transient hypotension 
induced by nitroprusside (NP) suggesting that the sympathetic branch has impaired. The effect of 
NP was blocked by a beta-adrenergic receptor blocker (β-blocker) propranolol. The Q175 mutants 
did not show a significantly altered response to transient hypertension induced by angiotensin II. 
HD patients complain of dizziness and light-headedness upon standing, all symptoms of 
baroreceptor dysregulation resulting in orthostatic hypotension. Data from [14,29]. 
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Figure 1. 3 
HRV is a measure of variation in the beat-to-beat (R-R) interval that reflects the dynamic balance 
of sympathetic and parasympathetic control of heart function. Traditionally, HRV is an indication 
of CV health and low HRV proposed as a predictor for CV disease and mortality. One of the most 
commonly used methods for evaluation of HRV is power spectral density analysis in which high-
frequency (HF) and low-frequency (LF) bands are extracted from the HRV signal, and the spectral 
power is calculated. Traditionally, the LF power is viewed as a measure of regulation by the 
sympathetic branch of the ANS, although it is more likely a general index of ANS function. We 
found robust daily and circadian rhythms in HRV and LP power in WT mice. As shown in the 
panels, HRV increased during sleep while LF power (sympathetic outflow) was higher when the 
mice were active. In the HD mutants (Q175), the HRV was low in young mutants and this 
reduction was largest during the rest phase. The power in the LF domain was significantly reduced 
in the young mutants with the biggest effects during the night. A similar reduction in HRV was 
previously observed in the BACHD line [10,13] as well as in the R6/1 model [41]. In HD patients, 
a similar decrease in HRV has also been reported during the presymptomatic and early stages of 
HD progression. 
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Figure 1. 4 
HR varies dramatically with a daily cycle in which HR is high during the active part of the 
sleep/wake cycle. As measured by telemetry, HD mutants (BACHD and Q175) exhibited highly 
pronounced tachycardia during their normal sleep time, with high HR and reduced amplitude in 
the HR rhythm. These changes suggest that ANS disruption occurs early in disease progression in 
these mutant lines. In agreement, we also saw evidence in the BACHD of the circadian system 
failing to lower blood pressure (BP) during sleep [29]. The HR rhythm is also disrupted in R6/1 
[41], R6/2 and HdhQ150 lines [46]. Therefore, overlapping data from several studies using 
different mouse models all found evidence for disrupted diurnal or circadian rhythms of HR. We 
have not seen evidence that this has been examined in HD patients, but the pre-clinical data 
supports 24-hr monitoring in patients.   
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Figure 1. 5 
The circuits involved in the generation of rhythms in HR and autonomic function are relatively 
well defined.  The central circadian clock in the suprachiasmatic nucleus (SCN) orchestrates the 
peripheral clocks via ANS. It appears that separate populations of SCN neurons project to the 
paraventricular nucleus (PVN) and innervate pre-sympathetic and pre-parasympathetic cell 
populations. These separate pre-sympathetic and pre-parasympathetic neurons project to either the 
preganglionic sympathetic neurons in the intermediolateral (IML) column of the spinal cord or the 
preganglionic neurons of the dorsal motor nucleus of the vagus (DMV). There are axon collaterals 
of the pre-sympathetic PVN neurons in the nucleus tractus solitarius (NTS). Both pathways 
innervate the heart to regulate HR via release of acetylcholine (ACh) and norepinephrine (NE). 
Also, the SCN regulates the HPA axis and the secretion of cortisol. The glucocorticoid receptors 
are also potent regulators of CV function. In HD patients, there is evidence for the degeneration of 
neurons in the SCN as well the brain stem. There is also evidence for the strong expression of p62 
immunopositive protein aggregates in axons of brainstem fiber tracts including the vagal nerve 
and the NTS [67].   
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Figure 2. 1 
Q175 mice exhibited altered diurnal and circadian resting HR rhythms. (A, B) The young Q175 
exhibited significantly different resting HR rhythms under both LD and DD. The effects were most 
striking under LD conditions where the mutants showed high resting HR. (C, D) By middle age, 
this tachycardia reversed and we actually saw low resting HR in the Hom Q175 under DD 
conditions. Please see Table 1 for results of statistical tests. Asterisks indicate P < 0.05 between 
the genotypes at each of the hourly bins (ZT or CT). 
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Figure 2. 2 
Q175 mice exhibited an abnormal relationship between HR and activity. (A) The young adult Hom 
Q175 exhibited high HR even while they exhibited low levels of activity. (B) By middle age, the 
Hom Q175 exhibited lower HR and lower activity in the night. WT data shown with black lines 
(HR) and fill (activity); the Het Q175 data are shown with gray lines (HR) and fill (activity); the 
Hom Q175 data are shown with red lines (HR) and fill (activity). (C) Q175 homozygotes exhibited 
significant loss of correlation of HR with activity levels (P < 0.001) in young mice. (D) By middle 
age, differences are diminished by the effects of aging and the progression of autonomic pathology 
in the mutants. WT data shown with black lines (HR) and fill (activity); Het Q175 data shown with 
gray lines (HR) and fill (activity); Hom Q175 data shown with red lines (HR) and fill (activity). 
WT, wild-type. 
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Figure 2. 3 
Q175 mice exhibited low HRV as measured at 3 months. (A) The young Q175 (Hom, Het) 
exhibited significantly reduced HRV. Most phases of the daily cycle were impacted. (B) The HF 
domain (1.5–5.0 Hz) was largely unaltered except at 2 phases late in the night. (C) The LF domain 
(0.2–1.5 Hz) was reduced in the mutants (Hom, Het) throughout the night. Please see Table 1 for 
results of statistical tests. Asterisks indicate P < 0.05 between the genotypes at each of the hourly 
bins (ZT or CT). 
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Figure 2. 4 
Baroreceptor evaluations were used to determine the autonomic responsivity to blood pressure 
perturbations (WT, n = 7; Het, n = 6; Hom, n = 9). As expected, the WT mice had normal reflex 
responses. (A) When the blood pressure was transiently lowered with nitroprusside (NP, 40 lg/kg), 
the heart rate was elevated. (B) When the blood pressure was transiently increased with angiotensin 
II (AT, 4 lg/kg), the heart rate dropped in compensation. The impact of ATII and NP were blocked 
by pretreatment with sympathetic and parasympathetic receptor antagonists (750 lg/kg propranolol, 
75 lg/kg glycopyrrolate). The Hom Q175 mice had very blunted HR responses to NP (n = 9). While 
some of the Het Q175 (2 out of 6 animals) showed a greatly reduced response to the NP injection, 
the overall NP-response was not significantly different from WT. WT, wild-type, ATII, 
administration of angiotensin II. 
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Figure 2. 5 
Echocardiogram indicates structural and functional differences early in the disease progression. 
Structural (A) and functional (B, C) parameters of the heart from WT (n = 8) and BACHD (n = 9) 
mice were measured from 3 to 15 mo of age. The age-dependent progression in heart dysfunction 
of Q175 mice was evaluated in a separate cohort of mice using echocardiograms starting at 3 
months of age and progressing to 12 months (WT, n = 12; Het, n = 10; Hom, n = 10). Both cardiac 
structural (Lv mass (D), EDD, ESD) and functional (Lv % FS, E/A ratio, and Lv EF (E)) deficits 
were observed and exhibited significant effects of age and genotype (Table 3). ^ P<0.05 within 
WT vs. 3 mo. # P<0.05 within BACHD vs. 3 mo. * P<0.05 for genotypic differences.  
(m
g)
D
E
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Figure 2. 6 
Histological analyses indicated heart pathology in the Q175 mouse. (A) Representative images of 
Masson’s trichrome stained hearts of each genotype showing that the gross dimensions of the Hom 
Q175 heart were strikingly smaller. (B) Mutants had reduced cardiomyocyte size as well as altered 
cytoarchitecture as shown by WGA staining. (C) Masson’s trichrome stain revealed greatly 
increased incidence of fibrotic lesions in Q175 Hom hearts. (D) These infarcts were present in 
each genotype, but were more common (about 3–4 folds) in both ventricles and anteriorly in the 
interventricular septum of the Hom Q175. Please see Table 5 and 6 for the results of statistical 
tests. Data are shown as the Mean ± SEM (n = 5–6 animals/genotype). *P < 0.05. The comparison 
between the number of infarcts was made with Kruskal–Wallis ANOVA followed by Dunn’s 
Multiple Comparison Test. 
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Figure 2. 7 
Histological analysis finds evidence of fibrosis and hypertrophy in the BACHD hearts. Examples 
of Masson’s Trichrome stained heart sections from 15 mo old WT and BACHD mice (A). 
Quantification of fibrosis by measuring the integrated density of fibrotic tissue and divided by 
tissue area detected significantly increased areas of fibrosis in BACHD mice (B). Examples of 
hematoxylin and eosin (H&E) stained heart sections from 15 mo old WT and BACHD mice (C). 
Morphometry measurements comparing heart weight relative to body weight between 15 mo old 
WT and BACHD mice (D). * P<0.05 for genotypic differences. 
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Figure 3. 1 
Genetic reduction of mHTT expression in the heart of BACHD mice. The full-length mHTT with 
two loxP sites enables cell specific reduction of mHTT using Cre-crecombinase (Cre). Mice 
hemizygous for the BACHD transgene will be crossed to mice hemizygous for the cardiomyocyte-
specific Myh6-Cre transgene. Approximately 25% of the offspring will be double transgenic 
(BACHD;Myh6-Cre), BMYO, with the mHtt floxed out in the cardiomyocytes.  
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Figure 3. 2 
Confirmation of the genetic reduction of human mHTT mRNA and protein expression in the heart 
in BMYO mice. (A) Quantification of mHtt expression levels normalized to GAPDH in the 
striatum and heart in WT, BACHD, and BMYO mice (n=3 per genotype; *P<0.05, **P<0.01, 
***P<0.001, ****P<0.0001, one-way ANOVA). (B) Western blot with the expanded polyQ 
specific antibody, 1C2, to detect mHTT protein levels in WT, BACHD, and BMYO mice. GAPDH 
was used as control. The following quantification shows the mHTT protein levels normalized to 
GAPDH in the striatum and heart of WT, BACHD, and BMYO mice.  n=3 per genotype; *P<0.05, 
one-way ANOVA.  
mHTT
GAPDH
Striatum
WT          BAC        BMYO
460
268
41
31
460
268
41
31
Heart
WT     BAC       BMYO
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Figure 3. 3 
Left ventricular (LV) ejection fraction and diastolic function were improved in BMYO mice. The 
ratio of early to late diastolic filling (E/A ratio). n=8 per genotype; *P<0.05 vs WT.  
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Figure 3. 4 
Hypertrophy and fibrosis markers were lower in BMYO hearts compared with BACHD hearts. 
The gene expression is normalized to GAPDH. n=3-4 per genotype; Age=6mo. *P<0.05.  
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Figure 3. 5 
Masson’s Trichrome staining showing fibrosis in the hearts of the BACHD and BMYO mice.  n=3 
per genotype. Age=6mo. Scale bar = 200 µm.  
 
 
 
 
 
 
 
 
 
 
 
 
WT BACHD BMYO
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Figure 3. 6 
Activity, rhythmic power, and grip strength are improved in BMYO mice. The averaged level of 
hourly cage activity (au/hr). The strength of the activity rhythm is indicated by the power (% 
variance) of the χ2 periodogram analysis. Grip strength (N/g) is maximal strength divided by the 
animal’s body weight. Total errors indicate the total number of errors made by an animal on the 
challenging beam test. Age = 6mo, n=5-8 per genotype; *P<0.05 vs WT.  
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Figure Appendix 1 
Relative gene expression of core clock, clock driven transcription factors, and metabolism genes 
in the hearts of the four groups of mice at ZT 2, 6, 10, 14, 18, and 22.  The relative expression is 
normalized to GAPDH (n=4 per group for each time point). The four groups are WT ad lib (WA), 
WT TRF (WT), BACHD ad lib (BA), and BACHD TRF (BT). Age = 6 mo.   
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Table 1 
Electrocardiographic parameters in young Q175 and WT animals held in a LD cycle. ECG values 
were continuously measured and placed into hourly bins  
One-way ANOVA was used to assess differences between the genotypes in the day or night. A 
paired t-test was used to access day/night differences within a genotype.  
 
 
 
 
 
 
 
 
 
 
 
 
 
  
98  
Table 2 
Echocardiographic parameters in Q175 and WT animals beginning at 3 mo of age. 
Two-dimensional, M-mode echocardiography and spectral Doppler images enabled measurement 
of heart dimension and function including Left ventricle mass (Lv mass), end-diastolic dimension 
(EDD), end-systolic dimension (ESD), posterior wall thickness (PWT), ventricular septal 
thickness (VST), aorta ejection time (Ao-ET), ratio of the early (E) to late (A) ventricular filling 
velocities (E/A ratio), fractional shortening (FS%), Lv Ejection Fraction (Lv EF).  
1 P < 0.05 significant difference compared to WT.  
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Table 3 
Two-way ANOVA was used to determine whether each of the echocardiographic parameters 
measured in Q175 and WT mice were significantly different. 
Genotype and age were the two factors. Measurements were made when the mice were 3, 6, 9, 
and 12 months of age.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Lv mass&
(mg) EDD&(mm) ESD&(mm) Ao!ET&(ms) FS&(%) Lv EF
Genotype F = 23.1,P < 0.001
F = 34.1,
P < 0.001
F = 6.1,
P = 0.003
F = 21.6,
P < 0.001
F = 8.6,
P < 0.001
F = 10.6,
P < 0.001
Age F = 6.4,P < 0.001
F = 6.6,
P < 0.001
F = 0.2,
P = 0.887
F = 3.1,
P = 0.031
F = 4.5,
P = 0.005
F = 5.0,
P = 0.003
Interaction F = 3.2,P = 0.006
F = 2.9,
P = 0.01
F = 0.5,
P = 0.780
F = 0.5,
P = 0.787
F = 1.6,
P = 0.156
F = 1.5,
P = 0.197
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Table 4 
Echocardiographic parameters in BACHD and WT animals beginning at 3 mo of age. 
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Table 5 
Morphological measurements in WT and Q175 mutants. were performed in heart coronal sections 
at the mid-ventricular level chosen based on the visual presence of papillary muscles in the left 
ventricle (Lv). 
Since the Lv were not perfectly round, we refer to the lumen measurements as 
circumference/perimeter. Values are presented as the Mean ± SEM. WT, n = 5; Het Q175, n = 6; 
Hom Q175, n = 6).  
• a P < 0.001 versus WT.  
• b P < 0.05.  
• c P < 0.005.  
• d P < 0.0005 versus WT.  
• e P < 0.05.  
• f P < 0.005 versus Het one-way ANOVA followed by Bonferroni's multiple comparison test.  
 
 
WT Het&Q175 Hom Q175
One!way&
ANOVA
Body&Weight&
(g) 28 ± 0.7 26 ± 0.4 21 ± 0.4a
F = 64.5,&
P < 0.001&
Heart&
Weight&(mg) 153 ± 4 151 ± 1 125 ± 2a
H = 19.4,&
P < 0.001&
Total&heart&
cross&
sectional&
area&(mm2)&
31.2 ±1.3 27.1 ±1.7 20.7 ±0.7d,f F = 16L&P = 0.0002&
Circumferen
ce/perimeter&
(mm)
20.0 ±0.3 18.8 ±0.6 17.2 ±0.5c F = 7.9L&P = 0.0049&
Interventricul
ar&septum&
thickness&
(mm)
1.1 ± 0.1 1.1 ± 0.1 1.0 ± 0.06 F = 0.6,&P = 0.561&
Lv&thickness&
(mm) 1.09 ±0.06 1.09 ±0.07 1.12 ±0.05
F = 0.08,&
P = 0.917&
Lv&lumen&
cross&
sectional&
area&(mm2)&
8.9 ± 1.0 6.8 ± 0.&6 4.0 ± 0.3d,e F = 13.7,&P = 0.0005&
Lv&lumen&
circumferenc
e/perimeter&
(mm)
10.7 ±0.6 10.0 ±0.6 8.2 ± 0.5b F = 5.26L&P = 0.0198
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Table 6 
Histological measurements of hearts of 15 mo WT and BACHD mice. 
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Table 7 
Echocardiographic parameters in BACHD, BMYO and WT animals at 3 mo and 6 mo of age. 
Two-dimensional, M-mode echocardiography and spectral Doppler images enabled 
measurement of heart dimension and function including Left ventricle mass (Lv mass), end-
diastolic dimension (EDD), end-systolic dimension (ESD), posterior wall thickness (PWT), 
ventricular septal thickness (VST), ratio of the early (E) to late (A) ventricular filling velocities 
(E/A ratio), fractional shortening (FS%), Lv Ejection Fraction (Lv EF), heart rate (HR). One-way 
ANOVA was used to evaluate the possible significance of the findings. If normality or equal 
variance tests failed, then a Kruskal-Wallis one way ANVOA on ranks was used instead.   
 
 BACHD BMYO WT Stats 
Age (mo) 3 3 3  
Lv mass (mg) 62 ± 6 64 ± 4 54 ± 4 F(2) = 1.784; P = 0.193 
EDD (mm) 4.0 ± 0.1 4.0 ± 0.1 4.0 ± 0.1 F(2) = 0.023; P = 0.977 
ESD (mm) 2.6 ± 0.1 2.8 ± 0.2 2.5 ± 0.2 F(2) = 1.111; P = 0.348 
Ao-ET (ms) 58 ± 1 59 ± 1 55 ± 2 F(2) = 3.668; P = 0.043 
FS (%) 30 ± 2 35 ± 1 37 ± 2 F(2) = 3.186; P = 0.062 
E/A 1.9 ± 0.1 2.0 ± 0.1 2.0 ± 0.1 F(2) = 0.027; P = 0.973 
Lv EF 63 ± 2 68 ± 1 71 ± 3 F(2) = 3.952; P = 0.035 
HR (bpm) 459 ± 10 481 ± 10 514 ± 23 H(2) =3.126; P = 0.209 
     
Age (mo) 6 6 6  
Lv mass (mg) 66 ± 4 68 ± 2 55 ± 2 F(2) = 5.210; P = 0.015 
EDD (mm) 4.2 ± 0.1 4.2 ± 0.1 4.1 ± 0.1 F(2) = 2.149; P = 0.142 
ESD (mm) 2.6 ± 0.1 2.8 ± 0.2 2.5 ± 0.2 F(2) = 1.111; P = 0.348 
Ao-ET (ms) 53 ± 2 51 ± 2 54 ± 2 F(2) = 0.647; P = 0.534 
FS (%) 30 ± 2 35 ± 1 37 ± 2 F(2) = 3.186; P = 0.062 
E/A 1.9 ± 0.1 2.0 ± 0.1 2.0 ± 0.1 F(2) = 0.027; P = 0.973 
Lv EF 63 ± 2 69 ± 2 71 ± 2 F(2) = 6.689; P = 0.006 
HR (bpm) 457 ± 8 512 ± 10 494 ± 12 H(2) = 6.743; P = 0.034 
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Table 8 
Quantitative real-time PCR (RT-qPCR) measurements of gene expression in the hearts of 
BACHD, BMYO and WT animals at 6 mo of age. Primers targeted collagen 1a (Col1a), myosin 
heavy chain, α isoform (Myh6), ventricular/slow myosin heavy chain isoform (Myh7), MYH7 
genecardiac sarcomeric genes, Myh6 and Myh7, the GATA4 transcription factor (GATA4), and 
brain natriuretic peptide (BNP).  In each case, expression was normalized to the expression of 
GAPDH. One-way ANOVA was used to evaluate the possible significance of the findings. If 
normality or equal variance tests failed, then a Kruskal-Wallis one way ANVOA on ranks was 
used instead.   
 BACHD BMYO WT Stats 
Col1a 0.0156 ± 0.005 
0.0031 ± 
0.003 
0.0002 ± 
0.0001 F(2) = 6.410; P = 0.026 
Myh6 1.179 ± 0.254 
0.185 ± 
0.118 
0.027 ± 
0.0.010 F(2) = 15.245; P = 0.003 
Myh7 0.020 ± 0.012 
0.005 ± 
0.003 
0.001 ± 
0.0003 F(2) = 2.095; P = 0.194 
GATA4 0.0011 ± 0.0003 
0.00001 ± 
0.00004 
0.00002 ± 
0.000006 H(2) = 7.318; P = 0.004 
BNP 0.006 ± 0.002 
0.003 ± 
0.0003 
0.002 ± 
0.0003 H(2) = 6.745; P = 0.010 
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Table 9 
Behavioral measurements of motor function from BACHD, BMYO and WT animals at 6 mo of 
age. Infrared monitors were used to measure total cage activity over a 10-day duration. The 
average activity levels during a 24 hr cycle are reported below.  In addition, the strength of 
diurnal rhythms in cage activity were assessed using periodogram and the results reported as 
power (% variation).  Maximal forelimb grip strength was measured by a meter during the night 
and normalize to body weight.  Finally, performance on a challenging beam was measured and 
the number of errors (mis-steps) are shown below. One-way ANOVA was used to evaluate the 
possible significance of the findings. If normality or equal variance tests failed, then a Kruskal-
Wallis one way ANVOA on ranks was used instead. Age = 6 mo.    
 
 BACHD BMYO WT Stats 
Activity (a.u) 
per 24 hrs 2504 ± 224 
2884 ± 
227 4741 ± 317 F(2) = 21.440; P < 0.001 
Power (% 
variation) 26.0 ± 0.9 27.0 ± 1.9 35.8 ± 1.1 F(2) = 17.053; P < 0.001 
Grip strength 
(N/g) 
0.083 ± 
0.003 
0.090 ± 
0.002 
0.097 ± 
0.003 F(2) = 5.323; P = 0.013 
Challenging 
beam (errors) 20.2 ± 2.1 27.0 ± 2.4 16.9 ± 2.1 H(2) = 7.802; P = 0.020 
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